var title_f23_60_24512="Algorithm ETT angio chest pain";
var content_f23_60_24512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: exercise testing in patients with suspected ischemic heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 643px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. ACC/AHA 2002 Guideline Update for Exercise Testing at file://www.acc.org/clinical/guidelines/exercise/dirIndex.htm. Copyright 2002 by the American College of Cardiology and American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24512=[""].join("\n");
var outline_f23_60_24512=null;
var title_f23_60_24513="Patient information: Hand, foot, and mouth disease (The Basics)";
var content_f23_60_24513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hand, foot, and mouth disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hand-foot-and-mouth-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5696190\">",
"      <span class=\"h1\">",
"       What is hand, foot, and mouth disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hand, foot, and mouth disease is an infection that causes painful sores to form in the mouth, and on the hands, feet, buttocks, and sometimes the genitals. A related infection, called &ldquo;herpangina,&rdquo; causes sores to form in the mouth. Both infections most often affect children, but adults can get them, too. This article is about hand, foot, and mouth disease, but herpangina and hand, foot, and mouth disease are treated the same.",
"     </p>",
"     <p>",
"      Hand, foot, and mouth disease usually goes away on its own within 2 to 3 days. There are treatments to help with its symptoms. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696205\">",
"      <span class=\"h1\">",
"       What are the symptoms of hand, foot, and mouth disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is sores that form in the mouth, and on the hands, feet, buttocks, and sometimes the genitals. These sores can be painful or hurt when touched. The sores in the mouth can make swallowing painful. The infection also usually causes fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696220\">",
"      <span class=\"h1\">",
"       How does hand, foot, and mouth disease spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The virus that causes",
"      <strong>",
"      </strong>",
"      hand, foot, and mouth disease can travel in body fluids of an infected person. For example, the virus can be found in:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Mucus from the nose",
"       </li>",
"       <li>",
"        Saliva",
"       </li>",
"       <li>",
"        Fluid from one of the sores",
"       </li>",
"       <li>",
"        Traces of bowel movements &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with hand, foot, and mouth disease are most likely to spread the infection during the first week of their illness. But the virus can live in their body well after the symptoms have gone away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696237\">",
"      <span class=\"h1\">",
"       Is there a test for hand, foot, and mouth disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, but it is not usually necessary. The doctor or nurse should be able to tell if your child has it by learning about your child&rsquo;s symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696252\">",
"      <span class=\"h1\">",
"       Should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call your child&rsquo;s doctor or nurse if your child is drinking less than usual and hasn&rsquo;t had a wet diaper for 4 to 6 hours (for babies and young children) or hasn&rsquo;t needed to urinate in the past 6 to 8 hours (for older children). You should also call your child&rsquo;s doctor or nurse if your child seems to be getting worse or isn&rsquo;t getting better after a few days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696267\">",
"      <span class=\"h1\">",
"       How is hand, foot, and mouth disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The infection itself is not treated. It usually goes away on its own within a few days. But children who are in pain can take nonprescription medicines such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;) or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;) to relieve pain. Never give",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      to a child younger than 18 years. In children, aspirin can cause a serious problem called Reye syndrome.",
"     </p>",
"     <p>",
"      The sores in the mouth can make swallowing painful, so some children might not want to eat or drink. It is important to make sure that children get enough fluids so that they don&rsquo;t get dehydrated. Cold foods, like popsicles and ice-cream, can help to numb the pain. Soft foods, like pudding and gelatin, might be easier to swallow.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5696282\">",
"      <span class=\"h1\">",
"       Can hand, foot, and mouth disease be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The most important thing you can do to prevent the spread of this infection is to wash your hands often with soap and water. You should also teach your children to wash often, especially after using the bathroom. It&rsquo;s also important to keep your home clean and to disinfect tabletops, toys, and other things that a child might touch. &nbsp; &nbsp;",
"     </p>",
"     <p>",
"      If your child has hand, foot, and mouth disease, keep him or her away from other people during the first week of the illness.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/60/24513?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83075 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24513=[""].join("\n");
var outline_f23_60_24513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696190\">",
"      What is hand, foot, and mouth disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696205\">",
"      What are the symptoms of hand, foot, and mouth disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696220\">",
"      How does hand, foot, and mouth disease spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696237\">",
"      Is there a test for hand, foot, and mouth disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696252\">",
"      Should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696267\">",
"      How is hand, foot, and mouth disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5696282\">",
"      Can hand, foot, and mouth disease be prevented?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24514="Patient information: Factor V Leiden (The Basics)";
var content_f23_60_24514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86010\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"         Deep veins of the leg",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/32/24067\">",
"         Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Factor V Leiden (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1823182141\">",
"      <span class=\"h1\">",
"       What is factor V Leiden?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Factor V Leiden is a condition that makes blood more likely to form clots in the legs, lungs, and other parts of the body.",
"     </p>",
"     <p>",
"      Blood clots can be dangerous. If a clot forms inside a blood vessel, it can clog the vessel and keep blood from getting where it needs to go. If a clot travels to the lungs, it can cause breathing problems or even death.",
"     </p>",
"     <p>",
"      Factor V Leiden is a life-long condition that people are born with. It is caused by an abnormal gene. Parents pass the abnormal gene to their child. Often, parents might not know they have the abnormal gene because they don&rsquo;t have any symptoms of the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182156\">",
"      <span class=\"h1\">",
"       What are the symptoms of factor V Leiden?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Factor V Leiden does not cause symptoms unless a blood clot happens. Symptoms of a clot can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warmth, redness, pain, and swelling in the leg &ndash; These are symptoms of a condition called &ldquo;deep vein thrombosis&rdquo; or &ldquo;DVT.&rdquo; This is a blood clot in a vein deep inside the leg (",
"        <a class=\"graphic graphic_figure graphicRef70603 \" href=\"UTD.htm?24/47/25343\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Breathing problems, sharp chest pain, coughing, and fast heartbeat &ndash; These are symptoms of a condition called &ldquo;pulmonary embolism.&rdquo; This is a blood clot in the lungs.",
"       </li>",
"       <li>",
"        Headache, trouble moving or talking, and seizures &ndash; These can be symptoms of a type of stroke caused by factor V Leiden.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182197\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you think you might have a blood clot in your leg. If you have symptoms of a stroke or a blood clot in the lungs, call 9-1-1. These conditions are very serious and can be life-threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182212\">",
"      <span class=\"h1\">",
"       Is there a test for factor V Leiden?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have factor V Leiden, he or she can order a blood test to look for the abnormal gene.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182227\">",
"      <span class=\"h1\">",
"       How is factor V Leiden treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If factor V Leiden causes a blood clot, the main treatment is medicines that get rid of clots or keep them from getting bigger. Some of these medicines come in shots and others come in pills. Doctors sometimes do surgery to remove a blood clot in the lungs or help with brain problems from a stroke.",
"     </p>",
"     <p>",
"      People who have had a blood clot usually take a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      &nbsp;(brand name: Coumadin) by mouth for at least 3 months after the clot is found. This medicine helps keep new blood clots from forming. It is important because people who have 1 clot often have another later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182242\">",
"      <span class=\"h1\">",
"       Is there anything I can do to prevent blood clots?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People sometimes get clots because they have been sitting still for too long. Taking a long trip raises your risk of blood clots, especially if you fly. To help prevent a clot on a long plane trip, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stand up and walk around every hour or 2",
"       </li>",
"       <li>",
"        Not smoke just before a plane trip",
"       </li>",
"       <li>",
"        Wear loose, comfortable clothes",
"       </li>",
"       <li>",
"        Change your sitting position and move your legs and feet often",
"       </li>",
"       <li>",
"        Drink plenty of fluids",
"       </li>",
"       <li>",
"        Wear knee-high compression stockings",
"       </li>",
"       <li>",
"        Avoid alcohol and medicines that make you sleepy &ndash; These can keep you from moving around enough.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women with factor V Leiden should ask a doctor or nurse if it is safe to take birth control pills. The hormones in these pills raise the risk of blood clots. This can be dangerous for women with factor V Leiden.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182259\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant or need surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant or need surgery, tell your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have had a blood clot",
"       </li>",
"       <li>",
"        Your father, mother, brother, or sister had a blood clot before age 50",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the doctor or nurse thinks you might have factor V Leiden, he or she can order a blood test to look for it. If you have it, you might need to take medicine to help prevent blood clots and other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1823182274\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"       Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/60/24514?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86010 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24514=[""].join("\n");
var outline_f23_60_24514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182141\">",
"      What is factor V Leiden?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182156\">",
"      What are the symptoms of factor V Leiden?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182197\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182212\">",
"      Is there a test for factor V Leiden?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182227\">",
"      How is factor V Leiden treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182242\">",
"      Is there anything I can do to prevent blood clots?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182259\">",
"      What if I want to get pregnant or need surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1823182274\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\">",
"      Deep veins of the leg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=related_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24515="Patient information: GI bleed (The Basics)";
var content_f23_60_24515=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16190\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/54/41826\">",
"         Patient information: Angiodysplasia of the GI tract (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/53/5971\">",
"         Patient information: Peptic ulcers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/10/17569\">",
"         Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/11/10418\">",
"         Patient information: Bloody stools in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/60/964\">",
"         Patient information: Peptic ulcer disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: GI bleed (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gi-bleed-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29049945\">",
"      <span class=\"h1\">",
"       What is a GI bleed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;GI&rdquo; stands for &ldquo;gastrointestinal.&rdquo; &ldquo;GI system&rdquo; (or &ldquo;GI tract&rdquo;) is the medical term for all the organs in your body that process food (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). The GI system includes your:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Esophagus (the tube that connects your mouth to your stomach)",
"       </li>",
"       <li>",
"        Stomach",
"       </li>",
"       <li>",
"        Small intestine (also known as the small bowel)",
"       </li>",
"       <li>",
"        Large intestine (also known as colon or large bowel)",
"       </li>",
"       <li>",
"        Rectum",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A GI bleed is when any of these organs start to bleed. Often you do not know you are bleeding, because it&rsquo;s happening inside your body. But sometimes there are signs that it is happening.",
"     </p>",
"     <p>",
"      There are 2 common types of GI bleeds. &ldquo;Upper GI bleeds&rdquo; affect the esophagus, the stomach, and the first part of the small intestine. &ldquo;Lower GI bleeds&rdquo; affect the colon and rectum. Bleeding can also happen in the middle of the small intestine, but this is much less common. This is sometimes called &ldquo;mid-GI bleeding.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049952\">",
"      <span class=\"h1\">",
"       What are the symptoms of a GI bleed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are a bit different depending on whether you have an upper or lower GI bleed. Some people have no symptoms. They find out they have bleeding when a doctor or nurse does a rectal exam on them.",
"     </p>",
"     <p>",
"      The symptoms of an upper GI bleed can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vomiting blood or something that looks like coffee grounds",
"       </li>",
"       <li>",
"        Diarrhea or bowel movements that look like black tar (this can happen with lower GI bleeds, too, but it is less common)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms of a lower GI bleed can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bowel movements that look bloody (this can happen with upper GI bleeds, too, but it is less common)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms that can happen with either an upper or lower GI bleed include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling weak, light-headed, or woozy (especially if you lose a lot of blood)",
"       </li>",
"       <li>",
"        A racing heartbeat (if you lose a lot of blood)",
"       </li>",
"       <li>",
"        Cramps or belly pain",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Pale skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049959\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vomit blood or something that looks like coffee grounds",
"       </li>",
"       <li>",
"        Have a bowel movement that looks like tar or has blood in it",
"       </li>",
"       <li>",
"        Feel weak, light-headed, or woozy",
"       </li>",
"       <li>",
"        Have a racing heartbeat",
"       </li>",
"       <li>",
"        Have severe belly pain",
"       </li>",
"       <li>",
"        Turn much paler than normal &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049966\">",
"      <span class=\"h1\">",
"       What can cause a GI bleed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes of GI bleeds include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ulcers in the stomach or small intestines (ulcers are sores on the lining of the GI tract)",
"       </li>",
"       <li>",
"        Swollen veins in the esophagus called &ldquo;varices&rdquo;",
"       </li>",
"       <li>",
"        Abnormal blood vessels called &ldquo;arteriovenous malformations&rdquo; (or AVMs, for short)",
"       </li>",
"       <li>",
"        Diverticulosis (a condition in which tiny pouches form in the lining of the gut) &nbsp;",
"       </li>",
"       <li>",
"        Crohn&rsquo;s disease or ulcerative colitis (conditions that can cause sores to form in the lining of the gut)",
"       </li>",
"       <li>",
"        Swollen veins in the rectum called &ldquo;hemorrhoids&rdquo; or tears around the anus",
"       </li>",
"       <li>",
"        Cancer (rarely)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049973\">",
"      <span class=\"h1\">",
"       Is there a test for a GI bleed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have a GI bleed, he or she will order 1 or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests to:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        See if you have enough red blood cells (the cells that carry oxygen)",
"       </li>",
"       <li>",
"        See if your blood is clotting normally",
"       </li>",
"       <li>",
"        See if your liver is working normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An endoscopy &mdash; For this test, a doctor gives you medicine to make you sleepy and relaxed. Then he or she puts a thin tube called an endoscope in your mouth and down your throat. The tube has a light on the end and a camera that sends images of your GI tract to a TV screen. If the doctor sees any spots that are bleeding, he or she can use tools that go through the endoscope to help stop the bleeding.",
"       </li>",
"       <li>",
"        A colonoscopy &mdash; This test is similar to an endoscopy, but it involves going in through the rectum (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). &nbsp;",
"       </li>",
"       <li>",
"        Imaging tests that involve putting a dye or weakly radioactive chemical into the blood so that doctors can trace where the blood goes &nbsp;",
"       </li>",
"       <li>",
"        A capsule endoscopy &mdash; This test uses a small camera about the size of a vitamin pill. You swallow the camera, and it sends pictures to a recording device that you wear on a belt for 8 hours. A doctor then looks at the pictures. This test lets doctors look at the small intestine, which is hard to see with endoscopy or colonoscopy because it is very long. After the test, the camera will pass with a bowel movement. Most people never see it come out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049980\">",
"      <span class=\"h1\">",
"       How is a GI bleed treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Depending on how much blood you have lost and what seems to be causing your bleeding, you might get 1 or more of these treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Oxygen through a mask or a tube that sits under your nose &nbsp;",
"       </li>",
"       <li>",
"        Blood or fluids into one of your veins (to replace blood you lost)",
"       </li>",
"       <li>",
"        Medicines to reduce stomach acid",
"       </li>",
"       <li>",
"        Medicines help clean out and empty your gut (so that doctors can see clearly what is happening inside)",
"       </li>",
"       <li>",
"        Antibiotics",
"       </li>",
"       <li>",
"        A small tube that goes up your nose and down your throat so doctors can rinse out your stomach",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on where the bleed seems to be, you might also have an endoscopy, a colonoscopy, or both. This can help the doctors find the spot or spots that are bleeding. Plus, doctors can sometimes use the endoscope or colonoscope to seal off blood vessels and stop them from bleeding.",
"     </p>",
"     <p>",
"      After the bleeding has stopped, your doctor or nurse will probably want to follow up with you to learn why you started bleeding in the first place. If you have ulcers or another condition that could lead to bleeding, the doctor or nurse will want to make sure those problems are treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29049987\">",
"      <span class=\"h1\">",
"       Can a GI bleed be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting a GI bleed by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not taking medicines called NSAIDs too often, unless your doctor tells you it is OK. Some people need to take these medicines on a regular basis, but they can increase the risk of bleeding. Examples of these medicines include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;). If you have to take these medicines on a regular basis, your doctor might give you another medicine to decrease your risk of bleeding.",
"       </li>",
"       <li>",
"        Being treated for stomach ulcers if you have them &nbsp;",
"       </li>",
"       <li>",
"        Taking medicines called beta blockers if you have cirrhosis and your doctor prescribes them",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29050100\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       Patient information: Peptic ulcers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"       Patient information: Angiodysplasia of the GI tract (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/11/10418?source=see_link\">",
"       Patient information: Bloody stools in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=see_link\">",
"       Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       Patient information: Peptic ulcer disease (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/60/24515?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16190 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.80-F9E9CAA6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24515=[""].join("\n");
var outline_f23_60_24515=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049945\">",
"      What is a GI bleed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049952\">",
"      What are the symptoms of a GI bleed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049959\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049966\">",
"      What can cause a GI bleed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049973\">",
"      Is there a test for a GI bleed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049980\">",
"      How is a GI bleed treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29049987\">",
"      Can a GI bleed be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29050100\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=related_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/11/10418?source=related_link\">",
"      Patient information: Bloody stools in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24516="X-ray blastic lytic and mixed metastases";
var content_f23_60_24516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    X-ray blastic lytic and mixed metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The images are from different patients and reflect different patterns of metastatic bone disease on plain x-ray. Red arrows indicate lytic disease and white arrows indicate blastic disease. Image A is a lateral skull x-ray from a patient with prostate carcinoma and shows two well defined blastic metastases (white arrows). Image B is a lateral skull x-ray from a patient with lytic metastatic disease, revealing a poor zone of transition between the lytic lesion and the normal surrounding bone (red arrows). Image C is from a patient with multiple myeloma and also shows lytic disease. The size of the lesions appear to be more uniform and have characteristic salt and pepper appearance. The lateral examination of the spine (D) is a patient with blastic metastases to the thoracic spine (single white arrow).&nbsp;Image (E) is a patient with lung carcinoma and has a lytic lesion in the right greater trochanter (red arrow). The metallic T shaped structure in the pelvis is an IUD. The patient displayed in image&nbsp;F is a patient with treated breast carcinoma with both lytic (red arrow) and blastic disease (white arrow) in the neck of the left femur.",
"    <div class=\"footnotes\">",
"     IUD: intrauterine device.",
"    </div>",
"    <div class=\"reference\">",
"     Images A, B, and C reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition, Lippincott Williams &amp; Wilkins, Philadelphia, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24516=[""].join("\n");
var outline_f23_60_24516=null;
var title_f23_60_24517="Chlorpheniramine, phenylephrine, and dextromethorphan: Drug information";
var content_f23_60_24517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine, phenylephrine, and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/39/30325?source=see_link\">",
"    see \"Chlorpheniramine, phenylephrine, and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardec&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Corfen-DM [OTC];",
"     </li>",
"     <li>",
"      De-Chlor DM [OTC];",
"     </li>",
"     <li>",
"      Ed A-Hist DM [OTC];",
"     </li>",
"     <li>",
"      EndaCof [OTC];",
"     </li>",
"     <li>",
"      Father John's&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PEH DM [OTC] [DSC];",
"     </li>",
"     <li>",
"      nasohist&trade; DM pediatric [OTC];",
"     </li>",
"     <li>",
"      Neo DM [OTC];",
"     </li>",
"     <li>",
"      NoHist DM [OTC];",
"     </li>",
"     <li>",
"      PE-Hist-DM [OTC];",
"     </li>",
"     <li>",
"      Virdec DM [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate, phenylephrine hydrochloride, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Relief of cough and cold symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, phenylephrine 5 mg, and dextromethorphan 5 mg per 15 mL: 30 mL every 4 hours (maximum: 180 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2-4 mg, phenylephrine 5-10 mg, and dextromethorphan 15 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Chlorpheniramine 4 mg, phenylephrine 10 mg, and dextromethorphan 20 mg: One tablet every 4-6 hours (maximum: 6 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate, phenylephrine hydrochloride, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Relief of cough and cold symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-5 years: Liquid: Chlorpheniramine 1 mg, phenylephrine 2.5 mg, and dextromethorphan 2.5 mg per 1 mL: 1 mL every 4-6 hours (maximum: 4 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chlorpheniramine 0.75 mg, phenylephrine 1.75 mg, and dextromethorphan 2.75 mg per 1 mL:  2 mL every 4-6 hours (maximum: 12 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chlorpheniramine 1 mg, phenylephrine 2-2.5 mg, and dextromethorphan 2.5-3 mg per 1 mL:  2 mL every 4-6 hours (maximum: 8 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chlorpheniramine 1 mg, phenylephrine 3.5 mg, and dextromethorphan 3 mg per 1 mL: 1 mL every 4-6 hours (maximum: 6 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chlorpheniramine 2-4 mg, phenylephrine 5-10 mg, and dextromethorphan 15 mg per 5 mL: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: Chlorpheniramine 4 mg, phenylephrine 10 mg, and dextromethorphan 20 mg:  One-half tablet every 4-6 hours (maximum: 3 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corfen-DM: Chlorpheniramine maleate 4 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     De-Chlor DM: Chlorpheniramine maleate 2 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; contains propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed A-Hist DM: Chlorpheniramine maleate 4 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [gluten free, sugar free; contains propylene glycol; banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Father John's&reg; Plus: Chlorpheniramine maleate 2 mg, phenylephrine hydrochloride 5 mg, and dextromethorphan hydrobromide 5 mg per 15 mL (118 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NoHist DM: Chlorpheniramine maleate 4 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PE-Hist-DM: Chlorpheniramine maleate 2 mg, phenylephrine hydrochloride 5 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardec&trade; DM: Chlorpheniramine maleate 1 mg, phenylephrine hydrochloride 3.5 mg, and dextromethorphan hydrobromide 3 mg per 1 mL (30 mL) [ethanol free, gluten free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EndaCof: Chlorpheniramine maleate 1 mg, phenylephrine hydrochloride 2.5 mg, and dextromethorphan hydrobromide 2.5 mg per 1 mL (59.2 mL) [dye free, ethanol free, gluten free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     nasohist&trade; DM pediatric: Chlorpheniramine maleate 1 mg, phenylephrine hydrochloride 2 mg, and dextromethorphan hydrobromide 3 mg per 1 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo DM: Chlorpheniramine maleate 0.75 mg, phenylephrine hydrochloride 1.75 mg, and dextromethorphan hydrobromide 2.75 mg per 1 mL (30 mL) [ethanol free, sugar free; contains propylene glycol; black cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Virdec DM: Chlorpheniramine maleate 1 mg, phenylephrine hydrochloride 3.5 mg, and dextromethorphan hydrobromide 3 mg per 1 mL (30 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Chlorpheniramine maleate 4 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxichlor PEH DM: Chlorpheniramine maleate 4 mg, phenylephrine hydrochloride 10 mg, and dextromethorphan hydrobromide 20 mg [scored] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of cough and upper respiratory symptoms associated with allergies or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine, phenylephrine, dextromethorphan, or any component of the formulation; use with or within 14 days of MAO inhibitor; severe hypertension or coronary artery disease; peptic ulcer disease; narrow-angle glaucoma; urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Donatussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-1-3 mg/mL (30 mL): $46.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Nasohist DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1-3 mg/mL (30 mL): $26.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Neo DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.75-0.75-2.75 mg/mL (30 mL): $49.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Norel CS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-4-12.5 mg/5 mL (473 mL): $52.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Phenylephrine-Chlorphen-DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-1-3 mg/mL (30 mL): $20.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.75-0.75-2.75 mg/mL (30 mL): $19.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Father Johns Medicine Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-4-10 mg/30 mL (118 mL): $5.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phenabid DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-3.5-28 mg (100): $231.59",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8865 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24517=[""].join("\n");
var outline_f23_60_24517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150253\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150242\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150249\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150243\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150229\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150219\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150230\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150251\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150222\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150250\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150226\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150238\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323063\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150233\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/39/30325?source=related_link\">",
"      Chlorpheniramine, phenylephrine, and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24518="Pentostatin: Pediatric drug information";
var content_f23_60_24518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentostatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"    see \"Pentostatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16021?source=see_link\">",
"    see \"Pentostatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nipent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nipent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1030385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite (Purine Antagonist)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1030414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"      see \"Pentostatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Adults (refer to individual protocols): Hydration with 500-1000 mL fluid prior to infusion and 500 mL after infusion is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hairy cell leukemia: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CLL: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 3 weeks, then every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cutaneous T-cell lymphoma: 3.75-5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     daily for 3 days every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute GVHD: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     daily for 3 days; may repeat after 2 weeks if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic GVHD: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks for 12 doses; then 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3-4 weeks (if still improving)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     The FDA-approved labeling does not contain renal dosage adjustment guidelines; use with caution in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Two patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-60 mL/minute achieved responses when treated with 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 70% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 60% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lathia, 2002:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nipent&reg;: 10 mg [contains mannitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1030419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Reconstitute with 5 mL SWI to a concentration of 2 mg/mL. The solution may be further diluted in 25-50 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W for infusion. Administer I.V. as a 20- to 30-minute infusion or as an I.V. bolus over 5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1030407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fludarabine, melphalan, ondansetron, paclitaxel, sargramostim",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1030403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); reconstituted vials and further dilutions are stable at room temperature for 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fludarabine, melphalan, ondansetron, paclitaxel, sargramostim",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1030386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hairy cell leukemia; other uses include treatment of cutaneous T-cell lymphoma, chronic lymphocytic leukemia (CLL), and acute and chronic graft-versus-host disease (GVHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentostatin may be confused with pentamidine, pentosan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nipent [U.S., Canada, and multiple international markets] may be confused with Nipin brand name for nifedipine [Italy, Singapore]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F182985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, AV block, bradycardia, cardiac arrest, chest pain, deep thrombophlebitis, facial edema, heart failure, hypertension , hypotension, pericardial effusion,  peripheral edema, sinus arrest, syncope, tachycardia, vasculitis, ventricular extrasystoles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams/thinking, amnesia, anxiety, ataxia, chills, CNS toxicity, confusion, depression, dizziness, emotional lability, encephalitis,  fatigue, fever, hallucination, headache, hostility, insomnia, meningism, nervousness, neuritis, neurosis, pain, seizure, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abscess, acne, alopecia, cellulitis, dry skin, eczema, furunculosis, petechial rash, photosensitivity, pruritus, rash, skin disorder, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, gout, hypercalcemia, hyponatremia, libido decreased/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, dysphagia, flatulence, gingivitis, glossitis, ileus, nausea/vomiting, oral moniliasis, stomatitis, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Acute leukemia, agranulocytosis, anemia, aplastic anemia, hemolytic anemia, hemorrhage, leukopenia, myelosuppression, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, dysarthria, hyperkinesia, myalgia, neuralgia, neuropathy, osteomyelitis, paralysis, paresthesia, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, conjunctivitis, eyes nonreactive, lacrimation disorder, photophobia, retinopathy, vision abnormal, watery eyes, xerophthalmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, earache, labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased, nephropathy, renal failure, renal insufficiency, renal function abnormal, renal stone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchitis, bronchospasm, cough, dyspnea, laryngeal edema, pharyngitis, pneumonia, pulmonary embolus, rhinitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, bacterial infection, diaphoresis, flu-like syndrome, herpes simplex, herpes zoster, infection, sepsis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Dysuria, fungal infection (skin), hematuria, lethargy, pulmonary edema, pulmonary toxicity (fatal; in combination with fludarabine), uveitis/vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1030390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentostatin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5994325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute); the terminal half-life is prolonged; appropriate dosing guidelines in renal insufficiency have not been determined. Severe rashes may occur and worsen with therapy continuation; may require withholding of treatment or discontinuation. Treatment should be temporarily withheld for active infections during therapy. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1030391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Severe CNS, renal, and liver toxicity have occurred with doses higher than recommended; do not exceed the recommended dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may cause elevations (reversible) in liver function tests. Severe pulmonary toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. Do not administer concurrently with fludarabine; concomitant use has resulted in serious or fatal pulmonary toxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Fatal pulmonary edema and hypotension have also been reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of a myeloablative regimen for bone marrow transplant. Bone marrow suppression may occur, primarily early in treatment and frequent monitoring of CBC during this time is necessary; if neutropenia persists beyond early cycles, evaluate for disease status. Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Pentostatin may enhance the cardiotoxic effect of Cyclophosphamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fludarabine: May enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelarabine: Pentostatin may diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegademase Bovine: May diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase Bovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenicity, maternal toxicity, and fetal loss. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5994363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, liver function, serum uric acid, renal function (creatinine clearance), bone marrow evaluation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1030408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentostatin is a purine antimetabolite that inhibits adenosine deaminase (ADA), preventing the deamination of adenosine to inosine. The resulting accumulation of deoxyadenosine (dAdo) and deoxyadenosine 5&prime;-triphosphate (dATP) reduces purine metabolism and DNA and  RNA synthesis. The greatest activity of ADA is in the cells of the lymphoid system, with T-cells having higher activity than B-cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1030410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 36.1 L (20.1 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ); rapidly to body tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution half-life: 11-85 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal half-life: 3-7 hours; renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute): 4-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~50% to 96%) within 24 hours (30% to 90% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults: 68 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     (mean)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1030425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16021?source=see_link\">",
"      see \"Pentostatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber. This drug can only be given by infusion on a specific schedule. Report immediately any redness, swelling, burning, or pain at infusion site; or signs of hypersensitivity (eg, respiratory difficulty or swallowing, chest tightness, rash, hives, swelling of lips or mouth). Maintain adequate hydration unless instructed to restrict fluid intake. You may be more susceptible to infection (avoid crowds and exposure to infection and do not have any vaccinations without consulting prescriber). May cause nausea and vomiting, or loss of appetite (small, frequent meals or frequent mouth care may help - or request medication from prescriber); headache (consult prescriber for approved analgesic); dizziness, confusion or lethargy (use caution when driving); or mouth sores (use frequent oral care with soft toothbrush or cotton swabs). Report signs of infection (eg, fever, chills, sore throat, mouth sores, burning urination, perianal itching, or vaginal discharge); unusual bruising or bleeding (eg, tarry stools, blood in urine, stool, or vomitus); vision changes or hearing; muscle tremors, weakness, or pain; CNS changes (eg, hallucinations, confusion, insomnia, seizures); or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      al-Razzak LA, Benedetti AE, Waugh WN, et al, &ldquo;Chemical Stability of Pentostatin (NSC-218321), a Cytotoxic and Immunosuppressant Agent,&rdquo;",
"      <i>",
"       Pharm Res",
"      </i>",
"      , 1990, 7(5):452-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/2367313/pubmed\" id=\"2367313\" target=\"_blank\">",
"        2367313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bolanos-Meade J, Jacobsohn DA, Margolis J, et al, &ldquo;Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(12):2661-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/15837980/pubmed\" id=\"15837980\" target=\"_blank\">",
"        15837980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Sorkin EM, &ldquo;Pentostatin. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Lymphoproliferative Disorders,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(4):652-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/ 7506651 /pubmed\" id=\" 7506651 \" target=\"_blank\">",
"        7506651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catovsky D, &ldquo;Clinical Experience With 2&prime;-Deoxycoformycin,&rdquo;",
"      <i>",
"       Hematol Cell Ther",
"      </i>",
"      , 1996, 38(Suppl 2):103-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/9137963/pubmed\" id=\"9137963\" target=\"_blank\">",
"        9137963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dillman RO, &ldquo;A New Chemotherapeutic Agent: Deoxycoformycin (Pentostatin),&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1994, 31(1):16-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/8122134/pubmed\" id=\"8122134\" target=\"_blank\">",
"        8122134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dillman RO, Mick R, and McIntyre OR, &ldquo;Pentostatin in Chronic Lymphocytic Leukemia: A Phase II Trial of Cancer and Leukemia Group B,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(4):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/2784491/pubmed\" id=\"2784491\" target=\"_blank\">",
"        2784491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grever MR, Siaw MFE, Jacob WF, et al, &ldquo;The Biochemical and Clinical Consequences of 2'-Deoxycoformycin in Refractory Lymphoproliferative Malignancy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1981, 57(3):406-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/6970050/pubmed\" id=\"6970050\" target=\"_blank\">",
"        6970050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsohn DA, Chen AR, Zahurak M, et al, &ldquo;Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(27):4255-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/17878478/pubmed\" id=\"17878478\" target=\"_blank\">",
"        17878478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane BJ, Kuhn JG, and Roush MK, &ldquo;Pentostatin: An Adenosine Deaminase Inhibitor For the Treatment of Hairy Cell Leukemia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(7-8):939-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/1504408/pubmed\" id=\"1504408\" target=\"_blank\">",
"        1504408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurzrock R, Pilat S, and Duvic M, &ldquo;Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(10):3117-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/10506607/pubmed\" id=\"10506607\" target=\"_blank\">",
"        10506607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lathia C, Fleming GF, Meyer M, et al, &ldquo;Pentostatin Pharmacokinetics and Dosing Recommendations in Patients With Mild Renal Impairment,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2002, 50(2):121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/12172976/pubmed\" id=\"12172976\" target=\"_blank\">",
"        12172976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Margolis J and Grever MR, \"Pentostatin (Nipent): A Review of Potential Toxicity and Its Management,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2000, 27(2 Suppl 5):9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/10877045/pubmed\" id=\"10877045\" target=\"_blank\">",
"        10877045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, Giles F, Duvic M, et al, &ldquo;Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies: Update of an M.D. Anderson Cancer Center Series,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(2):342-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/60/24518/abstract-text/14716770/pubmed\" id=\"14716770\" target=\"_blank\">",
"        14716770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13016 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24518=[""].join("\n");
var outline_f23_60_24518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709202\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182953\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182954\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030385\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030414\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182935\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182921\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030419\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030407\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030403\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030386\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182988\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182985\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030390\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994325\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030391\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299851\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182930\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182932\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182943\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994363\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030408\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030410\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1030425\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13016\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13016|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=related_link\">",
"      Pentostatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16021?source=related_link\">",
"      Pentostatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24519="Approach to neonatal cholestasis";
var content_f23_60_24519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to neonatal cholestasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Stephanie H Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Robert J Shulman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24519/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/60/24519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal cholestasis is generally defined as prolonged conjugated hyperbilirubinemia that occurs in the newborn period. It results from diminished bile flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excretion, which can be caused by a number of disorders. Neonatal cholestasis lasting more than two weeks affects approximately 1 in 2500 births (excluding infants with parenteral nutrition-associated cholestasis), but estimates vary depending on the definition used to define cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review provides an approach to patients with neonatal cholestasis. The pathogenesis and management of neonatal unconjugated hyperbilirubinemia and common causes of neonatal cholestasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestasis is defined as an impairment in the excretion of bile, which can be caused by defects in intrahepatic production or transmembrane transport of bile, or mechanical obstruction to bile flow. The biochemical features of cholestasis reflect the retention of components of bile in the serum (eg, bilirubin, bile acids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholesterol). The pattern and severity of each of these abnormalities varies with the underlying disorder. Elevated conjugated bilirubin is the predominant characteristic in most of the causes of neonatal cholestasis. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Conjugated hyperbilirubinemia in a neonate is defined as a serum conjugated bilirubin concentration greater than 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17.1",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    if the total serum bilirubin is &lt;5.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (85.5",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or greater than 20 percent of the total serum bilirubin if the total serum bilirubin is &gt;5.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (85.5",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    An elevated conjugated bilirubin is an abnormal finding and requires additional evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. The threshold is somewhat higher, usually a serum conjugated bilirubin greater than 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34.2",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    for defining clinically significant hyperbilirubinemia in infants with parenteral nutrition-associated liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link&amp;anchor=H2#H2\">",
"     \"Parenteral nutrition-associated liver disease in infants\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms &ldquo;conjugated bilirubin&rdquo; and &ldquo;direct bilirubin&rdquo; are often used interchangeably because conjugated bilirubin can be estimated by the &ldquo;direct&rdquo; reaction with a diazo reagent (van den Bergh reaction). However, direct-reacting bilirubin overestimates conjugated bilirubin, particularly when the concentrations of total serum bilirubin are high [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical aspects of serum bilirubin determination\", section on 'Measurement of serum bilirubin'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic jaundice (characterized by unconjugated hyperbilirubinemia) typically resolves by 14 days of age, but between 2 and 15 percent of newborns are still jaundiced at two weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although most of these infants have benign breast milk jaundice, a few will have biliary atresia which requires prompt diagnosis and treatment to optimize outcomes. The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) recommends that any infant noted to be jaundiced at the two-week well child visit should be evaluated for cholestasis (ie, conjugated hyperbilirubinemia) because some of these infants may not have another health care visit until they are two months old [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19842428#H19842428\">",
"     \"Biliary atresia\", section on 'Diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This approach results in screening between 60 and 375 healthy infants to detect one case of neonatal cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. To reduce the screening burden, NASPGHAN suggests the following approach in jaundiced infants who are most likely to have breast milk jaundice because they are exclusively or near-exclusively breast fed: the evaluation for cholestasis may be delayed until three weeks of age in such infants if they have a normal physical examination, no history of dark urine or light stools, and can be reliably monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12394983\">",
"    <span class=\"h2\">",
"     Initial screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating a jaundiced infant with cholestasis is to measure the serum concentrations of both total and conjugated bilirubin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the infant has",
"      <strong>",
"       unconjugated",
"      </strong>",
"      hyperbilirubinemia (&gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [34.2",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      at two weeks of age), this is often caused by breast milk jaundice, but other causes also should be considered, particularly if the total bilirubin is markedly elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"       \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17975?source=see_link\">",
"       \"Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      If the infant has",
"      <strong>",
"       conjugated",
"      </strong>",
"      hyperbilirubinemia, causes of cholestatic jaundice should be investigated, as discussed in the remainder of this topic. Conjugated hyperbilirubinemia is defined as a serum conjugated bilirubin concentration greater than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17.1",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the total bilirubin is &lt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or greater than 20 percent of the total bilirubin if the total bilirubin is &gt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stages of evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of an infant with conjugated hyperbilirubinemia is complex because many disorders can present with neonatal cholestasis (",
"    <a class=\"graphic graphic_table graphicRef64995 \" href=\"UTD.htm?13/32/13837\">",
"     table 1",
"    </a>",
"    ), and distinguishing among these disorders is difficult because of the lack of specific diagnostic tests. However, relatively few diagnoses account for the majority of cases (",
"    <a class=\"graphic graphic_table graphicRef79511 \" href=\"UTD.htm?3/24/3467\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/7\">",
"     7",
"    </a>",
"    ]. Neonatal hepatitis and biliary atresia, which typically occur in",
"    <strong>",
"     term",
"    </strong>",
"    infants, account for 70 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/7\">",
"     7",
"    </a>",
"    ] and alpha-1 antitrypsin deficiency accounts for another 5 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In",
"    <strong>",
"     premature",
"    </strong>",
"    infants, cholestasis more frequently results from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) or sepsis. The causes of neonatal cholestasis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link\">",
"     \"Biliary atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation should be undertaken in a staged approach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step is rapid diagnosis and early initiation of therapy of treatable disorders. Conditions such as sepsis, hypothyroidism, panhypopituitarism, and inborn errors of metabolism (eg, galactosemia) must be recognized and treated promptly to avoid significant progression of the illness. For infants in whom these disorders are excluded, consultation with a pediatric gastroenterologist is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biliary atresia must be identified early and differentiated from other causes of neonatal cholestasis because early surgical intervention (ie, before 2 months of age) results in a better outcome. Important steps in making this diagnosis are ultrasonography and liver biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19842428#H19842428\">",
"       \"Biliary atresia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional testing is directed at the diagnosis of specific conditions, such as Pi testing for alpha-1-antitrypsin deficiency, and sweat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gene testing for cystic fibrosis, and at potential complications of liver disease such as coagulopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain aspects of the history may be helpful in narrowing the differential diagnosis of neonatal cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. It is important to inquire about:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consanguinity (increases the risk of an autosomal recessive disorder)",
"     </li>",
"     <li>",
"      Congenital infections",
"     </li>",
"     <li>",
"      Prenatal ultrasonography and results (eg, presence of choledochal cyst or bowel anomalies)",
"     </li>",
"     <li>",
"      Isoimmune hemolysis (3 percent of infants with severe ABO incompatibility have conjugated hyperbilirubinemia that may persist until 2 weeks of age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/9\">",
"       9",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Neonatal infection, particularly urinary tract infection",
"     </li>",
"     <li>",
"      Dietary history (eg, breast milk or galactose-containing formula)",
"     </li>",
"     <li>",
"      Weight gain (neonatal hepatitis and metabolic disease may cause failure to thrive)",
"     </li>",
"     <li>",
"      Vomiting (may occur in metabolic disease, bowel obstruction, and pyloric stenosis)",
"     </li>",
"     <li>",
"      Stooling pattern (delayed stooling may occur in cystic fibrosis, hypothyroidism; diarrhea may occur in infection, metabolic disease, progressive familial intrahepatic cholestasis)",
"     </li>",
"     <li>",
"      Stool color &mdash; persistent acholic (clay colored) stools are specific, but not necessarily sensitive for biliary obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Urine color &mdash; dark urine suggests conjugated hyperbilirubinemia",
"     </li>",
"     <li>",
"      Excessive bleeding &mdash; may indicate coagulopathy, vitamin K deficiency",
"     </li>",
"     <li>",
"      Infant's disposition &mdash; irritability may indicate metabolic disease or sepsis; lethargy may indicate metabolic disease, sepsis, hypothyroidism, panhypopituitarism",
"     </li>",
"     <li>",
"      A history of similar problems in the parents or siblings &mdash; suggests a heritable disorder (eg, cystic fibrosis, alpha-1 antitrypsin deficiency, progressive familial intrahepatic cholestasis, Alagille syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of vital signs and growth parameters",
"     </li>",
"     <li>",
"      Assessment of general health (ill-appearance may indicate infection or metabolic disease, whereas infants with biliary atresia typically appear well)",
"     </li>",
"     <li>",
"      General appearance (infants with Alagille syndrome may exhibit characteristic facial appearance with a broad nasal bridge, triangular facies, and deep set eyes)",
"     </li>",
"     <li>",
"      General assessment of infant's vigor, tone, and symmetry",
"     </li>",
"     <li>",
"      Funduscopic examination (congenital infection, storage disease)",
"     </li>",
"     <li>",
"      Cardiac murmur or signs of heart failure (may be present in biliary atresia or Alagille syndrome)",
"     </li>",
"     <li>",
"      Abdominal examination (presence of ascites; abdominal wall veins; liver size, position, and consistency; spleen size and consistency; abdominal masses; umbilical hernia)",
"     </li>",
"     <li>",
"      Direct examination of the urine and stool to evaluate color (dark urine suggests conjugated hyperbilirubinemia; acholic [very pale] stools suggest cholestasis) (",
"      <a class=\"graphic graphic_figure graphicRef74099 \" href=\"UTD.htm?34/51/35639\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bruising or petechiae (coagulopathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies can help assess the extent of hepatobiliary dysfunction and may identify an etiology. Assessment of liver cell injury and biliary disorders should include total and conjugated bilirubin, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), serum alkaline phosphatase, and gamma-glutamyl transpeptidase (GGTP).",
"   </p>",
"   <p>",
"    Despite wide variability in serum GGTP concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/11\">",
"     11",
"    </a>",
"    ], GGTP may be helpful in the evaluation of neonatal cholestasis. Compared to age-specific norms, elevated serum GGTP is seen in many forms of neonatal liver disease, but primarily raises the concern for biliary atresia or other diseases that damage bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19842421#H19842421\">",
"     \"Biliary atresia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum bile acid concentration (consisting of cholic and chenodeoxycholic acids and their conjugates) is not routinely measured but can be helpful in identifying infants with inherited disorders of bile acid secretion or metabolism. Marked elevation of serum bile acids and cholesterol with relatively modest elevations of conjugated bilirubin and GGTP are characteristic of disorders of intrahepatic bile acid secretion, including progressive familial intrahepatic cholestasis, or disorders of bile acid synthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link&amp;anchor=H21#H21\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Progressive familial intrahepatic cholestasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of neonatal cholestasis\", section on 'Disorders of bile acid metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biosynthetic capacity of the liver is assessed by prothrombin and partial thromboplastin times (PT, PTT), which require clotting factors produced in the liver, and serum albumin and glucose concentrations. Blood ammonia concentration may be elevated if the liver's ability to clear endogenous substances from the circulation is impaired.",
"   </p>",
"   <p>",
"    Other studies include a complete blood count with platelet count, urinalysis with testing for reducing substances (to evaluate galactosemia), thyroid function tests, bacterial cultures of urine and blood, alpha-1 antitrypsin, and screening for cystic fibrosis (sweat chloride or mutation analysis). Acid-base status should be assessed with a bicarbonate concentration or pH as an initial step in the evaluation for metabolic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several imaging studies can assist in the diagnosis of patients with neonatal cholestasis. These include abdominal ultrasonography, hepatobiliary scintigraphy, magnetic resonance cholangiopancreatography (MRCP), and rarely endoscopic retrograde cholangiopancreatography (ERCP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19842428#H19842428\">",
"     \"Biliary atresia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, abdominal ultrasonography commonly is used as the initial test because it is non-invasive, easily available, and can identify structural abnormalities of the hepatobiliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. It is most helpful in the diagnosis of choledochal cysts but can also suggest the diagnosis of biliary atresia; suggestive findings for the latter are the inability to visualize the gallbladder and the presence of the triangular cord sign (triangular or bandlike periportal echogenic density &gt;3 mm in thickness) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one ultrasound study of 331 infants with an identifiable gallbladder, an irregular shape to the gallbladder and irregular wall had positive and negative predictive values for biliary atresia of 75 and 97 percent, respectively, when calculated from the same population of infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/16\">",
"     16",
"    </a>",
"    ]. The sensitivity and specificity of a small or absent gallbladder in detecting obstruction ranges from 73 to 100 percent and 67 to 100 percent, respectively when correlated with pathologic, surgical, and subsequent clinical examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatobiliary scintigraphy with technetium-labeled iminodiacetic acid analogs may provide more information in distinguishing biliary atresia from neonatal hepatitis and other causes of cholestasis. The test depends upon adequate hepatocellular function and patency of the biliary tract. Infants with biliary atresia usually have normal uptake of the isotope but absent excretion into the bile and intestine, whereas those with neonatal hepatitis typically have delayed uptake but appropriate excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/8\">",
"     8",
"    </a>",
"    ]. However, nonvisualization of the gallbladder or lack of excretion can occur in patients without biliary atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/17\">",
"     17",
"    </a>",
"    ]. Pretreatment for five days with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) increases the accuracy of this test by enhancing isotope excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/18\">",
"     18",
"    </a>",
"    ]. However, in most cases we do not use phenobarbital because it will delay diagnosis and does not obviate the need for liver biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19845741#H19845741\">",
"     \"Biliary atresia\", section on 'Hepatobiliary scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of scintigraphy in detecting obstruction ranges from 83 to 100 percent and 33 to 100 percent, respectively. This wide range is reflected in the variation in its use by different centers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. Scintigraphy adds little to the routine evaluation of the cholestatic infant, but may be of value in determining patency of the biliary tract, thereby excluding biliary atresia. However, it should never be relied upon solely to make a diagnosis in neonatal cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADDITIONAL TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2237521\">",
"    <span class=\"h2\">",
"     Cholangiogram",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2238170\">",
"    <span class=\"h3\">",
"     Open cholangiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the above steps in the evaluation support the diagnosis of biliary atresia, the infant should be taken to the operating room. The first step is an intraoperative cholangiogram, which is the gold standard in the diagnosis of biliary atresia. If the intraoperative cholangiogram demonstrates biliary obstruction (ie, if the contrast does not fill the biliary tree or reach the intestine), the surgeon should perform a hepatoportoenterostomy (Kasai procedure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19845794#H19845794\">",
"     \"Biliary atresia\", section on 'Cholangiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2237786\">",
"    <span class=\"h3\">",
"     ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is an alternative technique available at a few select tertiary care centers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. It involves endoscopic intubation of the biliary and pancreatic ducts through the ampulla of Vater with a small catheter and injection of contrast material to facilitate radiologic visualization of the ductal systems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20536?source=see_link\">",
"     \"ERCP for biliary disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ERCP appears to be a sensitive and specific means of detecting biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3,19-24\">",
"     3,19-24",
"    </a>",
"    ]. However, its utility in neonates is limited by the availability of appropriately sized endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/24\">",
"     24",
"    </a>",
"    ], the need for deep sedation or general anesthesia in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ], and the lack of validation. In select circumstances, ERCP can clarify the etiology of neonatal cholestasis and obviate the need for laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2237829\">",
"    <span class=\"h3\">",
"     MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance cholangiopancreatography (MRCP) may be another helpful modality in evaluating infants with neonatal cholestasis. Results from initial studies are encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. In two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/25,28\">",
"     25,28",
"    </a>",
"    ], the negative and positive predictive values of MRCP in detection of biliary atresia were 91 to 100 percent and 75 to 96 percent, respectively indicating that although it may aid in excluding the diagnosis, it should not be relied upon exclusively to identify infants with biliary atresia. In addition, it requires deep sedation or general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous liver biopsy is recommended for most infants with neonatal cholestasis, particularly when biliary tract obstruction is high on the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. Percutaneous liver biopsy can be performed safely in young infants and may be helpful in establishing a definitive diagnosis of cholestatic jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]. The NASPGHAN guideline recommends that a percutaneous liver biopsy be performed in most infants with undiagnosed cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. The biopsy should be interpreted by a pathologist with expertise in pediatric liver disease. Biopsy is recommended before performing a surgical procedure to diagnose biliary atresia. If the results are equivocal and biopsy was performed when the infant was &lt;6 weeks of age, repeat biopsy may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19845787#H19845787\">",
"     \"Biliary atresia\", section on 'Liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Duodenal aspirate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal aspirate analysis is an alternative to scintigraphy for assessing excretion of bile into the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3,30-32\">",
"     3,30-32",
"    </a>",
"    ]. In this test, fluid is obtained from the duodenum (either by placing a tube or string into the duodenum) and analyzed for bilirubin. Fluoroscopy may be required for correct tube placement. A test in which bilirubin concentration in the aspirate is less than or equal to that in the serum suggests biliary atresia. The sensitivity and specificity of duodenal aspirate analysis in detecting obstruction ranges from 91 to 100 percent and 43 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"     3",
"    </a>",
"    ]. Duodenal aspirate analysis may be useful in situations in which other tests to detect biliary obstruction are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any infant who is noted to be jaundiced at 2 weeks of age should be evaluated for cholestasis by measuring total serum bilirubin and conjugated (direct) bilirubin. The laboratory evaluation of breastfed infants who have a normal physical examination, normally colored stools and urine, and can be closely monitored may be delayed until they are 3 weeks of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conjugated hyperbilirubinemia is defined as conjugated bilirubin concentration greater than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17.1",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the total bilirubin is &lt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or more than 20 percent of the total bilirubin if the total bilirubin is &gt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of cholestatic jaundice in infants between two and eight weeks of age should be undertaken in a staged approach. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Stages of evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The initial step is rapid diagnosis and early initiation of therapy of treatable disorders (eg, sepsis, hypothyroidism, inborn errors of metabolism). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The next step is to distinguish biliary atresia from other causes of neonatal cholestasis, because early surgical intervention for biliary atresia results in improved outcome. Key steps are ultrasonography and liver biopsy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Liver biopsy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Additional testing is directed at the diagnosis of specific conditions and evaluation of associated complications (eg, coagulopathy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If jaundice fails to resolve in an infant in whom a treatable condition is diagnosed (eg, urinary tract infection or galactosemia) and treated, further evaluation should be performed.",
"     </li>",
"     <li>",
"      In the evaluation of an infant with cholestasis of unknown etiology, ultrasonography of the liver is almost always included and liver biopsy is usually indicated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scintigraphy and duodenal aspirate are not routinely recommended but may be useful in situations in which other tests are not readily available. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Scintigraphy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Duodenal aspirate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRCP and ERCP are not routinely recommended. However, if expertise in neonatal ERCP is available, this procedure can be used to detect extrahepatic obstruction, including biliary atresia or cholelithiasis. (See",
"      <a class=\"local\" href=\"#H2237786\">",
"       'ERCP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2237829\">",
"       'MRCP'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/1\">",
"      Dick MC, Mowat AP. Hepatitis syndrome in infancy--an epidemiological survey with 10 year follow up. Arch Dis Child 1985; 60:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/2\">",
"      Balistreri WF. Neonatal cholestasis. J Pediatr 1985; 106:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/3\">",
"      Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/4\">",
"      Davis AR, Rosenthal P, Escobar GJ, Newman TB. Interpreting conjugated bilirubin levels in newborns. J Pediatr 2011; 158:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/5\">",
"      Winfield CR, MacFaul R. Clinical study of prolonged jaundice in breast- and bottle-fed babies. Arch Dis Child 1978; 53:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/6\">",
"      Kelly DA, Stanton A. Jaundice in babies: implications for community screening for biliary atresia. BMJ 1995; 310:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/7\">",
"      el-Youssef M, Whitington PF. Diagnostic approach to the child with hepatobiliary disease. Semin Liver Dis 1998; 18:195.",
"     </a>",
"    </li>",
"    <li>",
"     McLin VA, Balistereri WF. Approach to neoonatal cholestasis. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario 2004. p.1079.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/9\">",
"      Sivan Y, Merlob P, Nutman J, Reisner SH. Direct hyperbilirubinemia complicating ABO hemolytic disease of the newborn. Clin Pediatr (Phila) 1983; 22:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/10\">",
"      Burton EM, Babcock DS, Heubi JE, Gelfand MJ. Neonatal jaundice: clinical and ultrasonographic findings. South Med J 1990; 83:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/11\">",
"      Manolaki AG, Larcher VF, Mowat AP, et al. The prelaparotomy diagnosis of extrahepatic biliary atresia. Arch Dis Child 1983; 58:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/12\">",
"      Wright K, Christie DL. Use of gamma-glutamyl transpeptidase in the diagnosis of biliary atresia. Am J Dis Child 1981; 135:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/13\">",
"      Maggiore G, Bernard O, Hadchouel M, et al. Diagnostic value of serum gamma-glutamyl transpeptidase activity in liver diseases in children. J Pediatr Gastroenterol Nutr 1991; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/14\">",
"      Kanegawa K, Akasaka Y, Kitamura E, et al. Sonographic diagnosis of biliary atresia in pediatric patients using the \"triangular cord\" sign versus gallbladder length and contraction. AJR Am J Roentgenol 2003; 181:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/15\">",
"      Tan Kendrick AP, Phua KB, Ooi BC, et al. Making the diagnosis of biliary atresia using the triangular cord sign and gallbladder length. Pediatr Radiol 2000; 30:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/16\">",
"      Farrant P, Meire HB, Mieli-Vergani G. Ultrasound features of the gall bladder in infants presenting with conjugated hyperbilirubinaemia. Br J Radiol 2000; 73:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/17\">",
"      Lee CH, Wang PW, Lee TT, et al. The significance of functioning gallbladder visualization on hepatobiliary scintigraphy in infants with persistent jaundice. J Nucl Med 2000; 41:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/18\">",
"      Majd M, Reba RC, Altman RP. Hepatobiliary scintigraphy with 99mTc-PIPIDA in the evaluation of neonatal jaundice. Pediatrics 1981; 67:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/19\">",
"      Iinuma Y, Narisawa R, Iwafuchi M, et al. The role of endoscopic retrograde cholangiopancreatography in infants with cholestasis. J Pediatr Surg 2000; 35:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/20\">",
"      Derkx HH, Huibregtse K, Taminiau JA. The role of endoscopic retrograde cholangiopancreatography in cholestatic infants. Endoscopy 1994; 26:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/21\">",
"      Wilkinson ML, Mieli-Vergani G, Ball C, et al. Endoscopic retrograde cholangiopancreatography in infantile cholestasis. Arch Dis Child 1991; 66:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/22\">",
"      Shirai Z, Toriya H, Maeshiro K, Ikeda S. The usefulness of endoscopic retrograde cholangiopancreatography in infants and small children. Am J Gastroenterol 1993; 88:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/23\">",
"      Guelrud M, Jaen D, Mendoza S, et al. ERCP in the diagnosis of extrahepatic biliary atresia. Gastrointest Endosc 1991; 37:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/24\">",
"      Ohnuma N, Takahashi T, Tanabe M, et al. The role of ERCP in biliary atresia. Gastrointest Endosc 1997; 45:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/25\">",
"      Norton KI, Glass RB, Kogan D, et al. MR cholangiography in the evaluation of neonatal cholestasis: initial results. Radiology 2002; 222:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/26\">",
"      Miyazaki T, Yamashita Y, Tang Y, et al. Single-shot MR cholangiopancreatography of neonates, infants, and young children. AJR Am J Roentgenol 1998; 170:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/27\">",
"      Jaw TS, Kuo YT, Liu GC, et al. MR cholangiography in the evaluation of neonatal cholestasis. Radiology 1999; 212:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/28\">",
"      Han SJ, Kim MJ, Han A, et al. Magnetic resonance cholangiography for the diagnosis of biliary atresia. J Pediatr Surg 2002; 37:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/29\">",
"      Fox VL, Cohen MB, Whitington PF, Colletti RB. Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1996; 23:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/30\">",
"      Penna FJ, Le&atilde;o E. Duodenal intubation in the differential diagnosis of obstructive jaundice in infants. Arq Gastroenterol 1982; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/31\">",
"      Larrosa-Haro A, Caro-L&oacute;pez AM, Coello-Ram&iacute;rez P, et al. Duodenal tube test in the diagnosis of biliary atresia. J Pediatr Gastroenterol Nutr 2001; 32:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24519/abstract/32\">",
"      Faweya AG, Akinyinka OO, Sodeinde O. Duodenal intubation and aspiration test: utility in the differential diagnosis of infantile cholestasis. J Pediatr Gastroenterol Nutr 1991; 13:290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5941 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24519=[""].join("\n");
var outline_f23_60_24519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12394983\">",
"      Initial screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stages of evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADDITIONAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2237521\">",
"      Cholangiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2238170\">",
"      - Open cholangiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2237786\">",
"      - ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2237829\">",
"      - MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Duodenal aspirate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5941|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/51/35639\" title=\"figure 1\">",
"      Stool color card used to screen infants for biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/32/13837\" title=\"table 1\">",
"      DDx neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/24/3467\" title=\"table 2\">",
"      Common causes cholestasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=related_link\">",
"      Biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20536?source=related_link\">",
"      ERCP for biliary disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17975?source=related_link\">",
"      Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24520="Craniopharyngioma";
var content_f23_60_24520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Craniopharyngioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Griffith R Harsh, IV, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Lawrence D Recht, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Karen J Marcus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24520/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/60/24520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniopharyngiomas are rare solid or mixed solid-cystic tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/1\">",
"     1",
"    </a>",
"    ]. Historically, these have also been referred to as Rathke pouch tumors or hypophyseal duct tumors.",
"   </p>",
"   <p>",
"    The epidemiology, pathology, diagnosis, management, and outcomes after treatment of craniopharyngiomas are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, there are an estimated 350 new cases of craniopharyngioma diagnosed each year, constituting approximately 1 to 3 percent of all brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Craniopharyngiomas comprise about 5 to 10 percent of brain tumors in children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In other parts of the world, craniopharyngiomas appear to be more common, with higher incidence rates reported in Japan and some parts of Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Craniopharyngiomas are approximately equally common in males and females.",
"   </p>",
"   <p>",
"    There is a bimodal age distribution, with one peak in children between 5 and 14 years, and a second peak in adults between 50 and 75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/2\">",
"     2",
"    </a>",
"    ]. Adamantinomatous craniopharyngiomas are more common in the pediatric age group, while papillary craniopharyngiomas are seen predominantly in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniopharyngiomas are epithelial tumors that arise in the sellar area. Although benign histologically, these tumors frequently shorten life and should be considered low-grade malignancies. Most craniopharyngiomas contain both solid and cystic components.",
"   </p>",
"   <p>",
"    In the World Health Organization classification of central nervous system tumors, craniopharyngiomas are divided into two categories, adamantinomatous craniopharyngiomas and papillary craniopharyngiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/7\">",
"     7",
"    </a>",
"    ]. The prognostic importance of tumor type is uncertain; larger series have found that these two histologic subtypes behave similarly with respect to resectability, sensitivity to radiation, and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Craniopharyngiomas vary in size from small, solid, well-circumscribed masses to huge multilocular cysts that invade the sella turcica and displace neighboring cerebral structures. The majority of craniopharyngiomas consist of one or more cysts that are filled with turbid fluid that contains cholesterol crystals. Malignant transformation is rare but has been reported, usually after multiple recurrences and radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Craniopharyngiomas usually arise in the pituitary stalk in the suprasellar region adjacent to the optic chiasm. A small percentage arises within the sella [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and a few tumors have been described within the optic system or the third ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor extension occurs in variable directions along the path of least resistance. The tumor may therefore extend into the basal cisterns or the base of the brain or displace the third ventricle superiorly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniopharyngiomas are slow growing, and symptoms often are present for a year or more before the diagnosis is established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A wide range of symptoms may be present, depending upon the precise location of the tumor and its relationship to adjacent normal structures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual symptoms &mdash; Visual symptoms are frequent, and deficits on formal ophthalmologic assessment are present in the majority of patients. These can be a direct result of pressure on the optic chiasm; the specific deficit depends upon the growth pattern of the tumor.",
"     </li>",
"     <li>",
"      Endocrine abnormalities &mdash; Direct damage to or compression of normal structures can lead to a range of endocrine abnormalities. Frequently observed complications include deficiencies of growth hormone, gonadotropin deficiency, thyroid stimulating hormone, and adrenocorticotropic hormone in an estimated 75, 40, 25 and 25 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/4\">",
"       4",
"      </a>",
"      ]. Diabetes insipidus is frequent when the pituitary stalk is involved.",
"      <br/>",
"      <br/>",
"      Growth failure, which can be caused by either hypothyroidism or growth hormone deficiency, is the most common presentation in children. Sexual dysfunction is the most common endocrine manifestation in adults; almost 90 percent of men complain of erectile dysfunction, while most women have amenorrhea.",
"     </li>",
"     <li>",
"      Headache &mdash; Severe headaches are present in approximately 50 percent of patients. These may reflect either increased intracranial pressure from the mass effect of the tumor itself, from obstructive hydrocephalus from tumor compression of the third ventricle, or from meningeal irritation by escaped cyst contents.",
"     </li>",
"     <li>",
"      Other symptoms &mdash; Craniopharyngiomas can also cause other generalized symptoms, such as depression, independent of any hormone deficiency. The presumed cause is extension of tumor into the frontal lobes, striocapsulothalamic areas, or limbic system. Nausea, vomiting, and lethargy can accompany pressure-related headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperatively, the diagnosis of craniopharyngiomas is usually suggested by the presence of a mass on magnetic resonance imaging (MRI)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT).",
"   </p>",
"   <p>",
"    Calcification in the suprasellar region is seen in 60 to 80 percent of patients with craniopharyngioma and one or more cysts are present in about 75 percent. Thus, a cystic calcified parasellar lesion is very likely to be a craniopharyngioma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70146 \" href=\"UTD.htm?34/50/35631\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72783 graphicRef80882 \" href=\"UTD.htm?16/3/16440\">",
"     image 2A-B",
"    </a>",
"    ). Calcifications can also sometimes be seen on plain skull radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61391 \" href=\"UTD.htm?37/59/38847\">",
"     image 3",
"    </a>",
"    ). In some patients, no calcification is seen on radiologic testing. In these patients, the diagnosis can only be established histologically.",
"   </p>",
"   <p>",
"    Craniopharyngiomas must be distinguished from other tumors in the parasellar area, including pituitary macroadenoma, meningiomas, optic gliomas, germinoma, teratomas, lymphoma, metastases, from non-neoplastic cysts (Rathke's, pars intermedia, and arachnoid), and from infiltrative disorders such as sarcoidosis and systemic histiocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Cysts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most patients with craniopharyngioma have at least partial hypopituitarism, endocrine testing, particularly of adrenal and thyroid function, is indicated before surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed neuroophthalmologic examination including visual field testing helps to determine whether there is compression of the optic pathways and establishes a presurgical baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Visual defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the optimal treatment of craniopharyngiomas has been controversial and included two basic approaches: aggressive surgery with an attempt to achieve complete resection at diagnosis versus a more conservative surgical approach that used radiation therapy (RT) to treat residual disease.",
"   </p>",
"   <p>",
"    Major advances in neurosurgical techniques have significantly decreased the morbidity and mortality associated with resection, making aggressive resection feasible in more cases. At the same time, improvements in RT techniques have permitted more accurate delivery of radiation to the tumor target, while minimizing radiation damage to normal structures. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An experienced multidisciplinary team (neurosurgery, radiation therapy, endocrinology, ophthalmology) is essential for the optimal treatment of both pediatric and adult patients with craniopharyngiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/4,18,19\">",
"     4,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is indicated in almost all cases. The goal of surgery is to establish the diagnosis, alleviate mass-related symptoms, and remove as much tumor as is safely possible. Some neurosurgeons advocate a strategy of reduction of neural compression by cyst drainage and limited resection of solid tumor in anticipation of irradiation of residual tumor. Many others argue that the initial operation offers the best chance for surgical cure and attempt complete total tumor removal when it can be accomplished with a low risk of neurologic injury.",
"   </p>",
"   <p>",
"    Preoperative management should include treatment of disease-related complications that may be present and can increase the risk associated with surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine function should be assessed and significant abnormalities corrected prior to surgery if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"       \"Diagnosis of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"       \"Treatment of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritumoral edema and increased intracranial pressure should be controlled. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hydrocephalus may require either a temporary or permanent shunt.",
"     </li>",
"     <li>",
"      Patients with a large cystic component to their tumor may require specific treatment (aspiration) prior to surgery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cyst management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical approach depends upon the location of the tumor. Intrasellar tumors may be removed transsphenoidally. An extended transsphenoidal approach, now commonly performed using the endoscope, can remove tumors with suprasellar extension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/20\">",
"     20",
"    </a>",
"    ]. Many craniopharyngiomas are currently approached by a pterional craniotomy. Far superior extension of a cyst into the third ventricle may require opening of the lamina terminalis or an approach from above, through the foramen of Monro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) can be used to treat patients with residual disease who have undergone a partial surgical resection or to treat disease that has recurred following what was initially thought to be a gross total resection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     RT techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary RT techniques permit greater treatment precision and conformity. These approaches decrease long-term toxicity by limiting the exposure of surrounding normal tissues to ionizing radiation. Techniques that have been used in the treatment of craniopharyngioma include stereotactic radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/21\">",
"     21",
"    </a>",
"    ] and radiosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/21-24\">",
"     21-24",
"    </a>",
"    ], intensity modulated radiation therapy (IMRT), and proton beam therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stereotactic techniques &mdash; Stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) utilize a fixation or other stable frame system that establishes a patient-specific coordinate system for the treatment process. Following frame placement, imaging studies are performed to localize the target volume within the fixation device coordinates. Fiducial markers attached to the frame and built-in scales indicate the coordinate system on images. The target is viewed and the position determined in the frame coordinates. Once the target is identified and the desired dose chosen, the treatment planning will then determine the field size, coordinates and relative weights to be delivered for coverage of the target. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"       \"Stereotactic cranial radiosurgery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      SRT uses a fractionated treatment schedule to minimize damage to normal structures, while allowing coverage of a relatively large target volume. SRS uses a single fraction of radiation and is an alternative to fractionated radiotherapy for small tumors or small focal postoperative residuals. Care must be taken to limit dose to the tolerance of the optic nerves, chiasm, and tracts.",
"     </li>",
"     <li>",
"      Intensity modulated RT &mdash; IMRT is a three-dimensional (3D) technique that optimizes the delivery of radiation to irregularly shaped volumes using complex treatment planning and dynamic delivery of irradiation. This technique can be added to 3D-conformal or stereotactic radiotherapy (whether delivered by photons or protons) to shape the beam to the irregular contours of the tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"       \"Intensity-modulated radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proton beam RT &mdash; Heavy particle irradiation techniques such as proton beam use charged particles rather than photons to deliver high doses of radiation to the target volume while limiting the \"scatter\" dose received by surrounding tissues. There is minimal radiation exposure beyond the Bragg peak, where the protons come to a halt and deliver their energy. This is particularly advantageous in treating tumors very near to critical structures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"       \"Proton and ion beams in cancer therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;For fractionated treatment schedules using conformal RT techniques, doses above 54 to 55 Gy significantly improve the likelihood of local tumor control compared to lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In a retrospective series, the recurrence rate was significantly higher in patients receiving &le;54 Gy compared with higher doses (50 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/27\">",
"     27",
"    </a>",
"    ]. The rates of radiation-induced endocrine, neurologic, and vascular sequelae are low with doses less than 61 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cyst management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques to decrease cyst size and thus help manage symptoms are generally used in patients with recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous aspiration of cyst contents has been used to alleviate symptoms, and intermittent aspiration may be recommended whenever total excision is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. An alternative is placement of an Ommaya reservoir system for intermittent aspiration of cysts that cannot be completely resected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Intracavitary irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach in patients with solitary or multicystic tumors is intracavitary irradiation via stereotactically applied radioisotopes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. Beta-emitting isotopes such as yttrium-90 (90Yt), rhenium-186 (186Rh), and phosphorus-32 (32P) are preferred because of the limited penetrance of the emitted energy and the relative ease of handling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intracavitary chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to intracystic therapy uses",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/42\">",
"     42",
"    </a>",
"    ]. Experience is more limited than with intracavitary irradiation, but in one series of 17 children, intracystic bleomycin was well tolerated, with five complete remissions and a median progression free interval of 1.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/43\">",
"     43",
"    </a>",
"    ]. This approach may have a role in delaying RT or aggressive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disease control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical resection is the goal of initial treatment, and improvements in surgical techniques have increased the frequency with which a complete resection can be achieved without excessive morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the benefits of surgery must be balanced against treatment-related morbidity. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    RT is widely used as an adjuvant following subtotal resection, and this approach significantly reduces the risk of a local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. The impact of adjuvant RT on overall survival is less clear, probably reflecting the effectiveness of RT as salvage therapy for recurrent disease. There are no randomized trials that compare adjuvant RT with observation followed by salvage RT for recurrent disease.",
"   </p>",
"   <p>",
"    The following reports from large series illustrate the range of findings using contemporary surgical and RT techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 75 patients treated for craniopharyngioma at a single institution over a 27-year period, all patients underwent an attempt at gross total excision [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/46\">",
"       46",
"      </a>",
"      ]. Postoperative RT was given to 18 of the 27 in whom only a subtotal resection was possible. RT was also given to 22 patients who experienced a local relapse following surgery alone. At a median follow-up of 7.6 years, the 10-year local control rate was significantly better for the patients with a subtotal resection plus RT compared to the 57 patients treated with surgery alone, 48 of whom originally had a complete resection (84 versus 42 percent). The overall survival for the entire cohort was 85 percent.",
"     </li>",
"     <li>",
"      In 121 cases treated between 1963 and 2002, 19 underwent gross total removal, 84 partial resection, and nine cyst evacuation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/47\">",
"       47",
"      </a>",
"      ]. All of the patients who were able to undergo gross total resection were recurrence free at 10 years. Among those managed with partial resection, the 10-year recurrence-free rates were 77 and 38 percent, with and without postoperative RT.",
"     </li>",
"     <li>",
"      Stereotactic RT (52 Gy in 1.8 Gy fractions) was used to treat 40 patients (28 with recurrent disease, 12 as an adjuvant after surgery) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/22\">",
"       22",
"      </a>",
"      ]. At a median follow-up of 98 months, local control was 100 percent at ten years and overall survival was 89 percent.",
"     </li>",
"     <li>",
"      46 patients with craniopharyngioma underwent 51 courses of treatment with SRS for residual or recurrent craniopharyngioma (median tumor volume 1.0 cm3) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/24\">",
"       24",
"      </a>",
"      ]. At a mean follow-up of over five years, the five-year overall and progression-free survival rates were 97 and 92 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of endocrine complications are observed in patients with craniopharyngioma following treatment. These are due in part to the original tumor but can be exacerbated by treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panhypopituitarism is present in the majority of cases and can be manifested by hypogonadism, hypothyroidism, adrenal insufficiency, or growth hormone deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"       \"Clinical manifestations of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"       \"Diagnosis of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"       \"Treatment of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothalamic dysfunction can cause disabling obesity, disorders of temperature regulation, sleep disorders, or diabetes insipidus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H28#H28\">",
"       \"Etiology and natural history of obesity\", section on 'Hypothalamic obesity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"       \"Treatment of central diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric and behavioral disorders are frequent in children, as is impaired intellectual functioning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired intellectual functioning (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypothalamic obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H27#H27\">",
"       \"Etiology and natural history of obesity\", section on 'Neuroendocrine obesity'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sleep disorders and a disrupted circadian rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Behavioral problems [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Visual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual deficits are present in the majority of patients prior to treatment. These may be exacerbated by either surgery or radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Vascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of vascular abnormalities have been reported when RT is a component of treatment for children with craniopharyngioma. As an example, in one series of 20 patients who underwent imaging following treatment, six had abnormalities, including temporal cavernomas, moyamoya syndrome, aneurysms, and decreases in arterial caliber [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Secondary malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of RT to treat craniopharyngiomas has been associated with the secondary development of malignant glial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H41#H41\">",
"     \"Complications of cranial irradiation\", section on 'Radiation-induced tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most recurrences are local, but remote recurrences can occur, possibly as a consequence of seeding through the cerebrospinal fluid during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. Treatment of recurrent disease is associated with significantly more morbidity and mortality than the initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     POST TREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based guidelines for follow-up following initial therapy. Key features of patient management include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroimaging with MRI, on an annual basis. The duration of imaging follow-up depends upon the extent of initial surgery, the presence or absence of residual tumor, and symptomatology.",
"     </li>",
"     <li>",
"      Monitoring of endocrine function with replacement hormone therapy as needed.",
"     </li>",
"     <li>",
"      Formal assessment of visual function including visual field testing postoperatively and on an annual basis thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H985761160\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis following treatment is influenced both by the ability to control tumor and the development of treatment-related complications. As an example, in one series of 121 cases, the 10-year survival rate following presentation was 90 percent when non-tumor related deaths were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this, late mortality appears to be increased in patients without tumor progression and may be related to complications of treatment. As an example, in a series of 41 patients treated over a 37-year period, there were nine deaths (22 percent) overall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24520/abstract/63\">",
"     63",
"    </a>",
"    ]. Three of these occurred more than 20 years after presentation, and one occurred between 10 and 20 years. None of these four were directly related to tumor progression. The reported causes of death in these four cases were uncontrolled diabetes insipidus, pontine infarction, panhypopituitarism, and liver failure.",
"   </p>",
"   <p>",
"    Many series have relatively short follow-up, and longer duration of follow-up is necessary to assess results. However, long-term studies often utilized older surgical and radiation therapy techniques, and patients treated with contemporary techniques may have better outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the patient with a craniopharyngioma involves a balance between controlling the disease and minimizing the side effects of treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals should be managed by a multidisciplinary team with experience in the treatment of craniopharyngioma. The team should include both neurosurgery and radiation therapy expertise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management approach is neurosurgical resection, which should resect as much of the tumor as possible, while avoiding severe treatment-induced deficits. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not able to undergo a complete resection of their tumor, we recommend postoperative radiation therapy rather than observation with salvage RT if a recurrence occurs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/1\">",
"      Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer 1976; 37:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/2\">",
"      Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998; 89:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/3\">",
"      Jane JA Jr, Laws ER. Craniopharyngioma. Pituitary 2006; 9:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/4\">",
"      Garr&egrave; ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr 2007; 19:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/5\">",
"      Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994; 23:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/6\">",
"      Izuora GI, Ikerionwu S, Saddeqi N, Iloeje SO. Childhood intracranial neoplasms Enugu, Nigeria. West Afr J Med 1989; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     Craniopharyngioma. In: World Health Organization Classification of Tumours of the Nervous System, Editorial and Consensus Conference Working Group, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon, France 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/8\">",
"      Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 1994; 35:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/9\">",
"      Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995; 83:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/10\">",
"      Rodriguez FJ, Scheithauer BW, Tsunoda S, et al. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 2007; 31:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/11\">",
"      Boongird A, Laothamatas J, Larbcharoensub N, Phudhichareonrat S. Malignant craniopharyngioma; case report and review of the literature. Neuropathology 2009; 29:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/12\">",
"      Laws ER Jr. Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980; 52:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/13\">",
"      NORTHFIELD DW. Rathke-pouch tumours. Brain 1957; 80:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/14\">",
"      Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982; 89:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/15\">",
"      Bollati A, Giunta F, Lenzi A, Marini G. Third ventricle intrinsic craniopharingioma. Case report. J Neurosurg Sci 1974; 18:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/16\">",
"      Cashion EL, Young JM. Intraventricular craniopharyngioma. Report of two cases. J Neurosurg 1971; 34:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/17\">",
"      Duff J, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000; 46:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/18\">",
"      Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis 2007; 2:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/19\">",
"      Honegger J, Tatagiba M. Craniopharyngioma surgery. Pituitary 2008; 11:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/20\">",
"      de Divitiis E, Cappabianca P, Cavallo LM, et al. Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas. Neurosurgery 2007; 61:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/21\">",
"      Minniti G, Esposito V, Amichetti M, Enrici RM. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev 2009; 32:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/22\">",
"      Combs SE, Thilmann C, Huber PE, et al. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007; 109:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/23\">",
"      Kobayashi T. Long-term results of gamma knife radiosurgery for 100 consecutive cases of craniopharyngioma and a treatment strategy. Prog Neurol Surg 2009; 22:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/24\">",
"      Niranjan A, Kano H, Mathieu D, et al. Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys 2010; 78:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/25\">",
"      Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006; 64:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/26\">",
"      Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 2006; 12:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/27\">",
"      Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys 1992; 24:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/28\">",
"      Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 1999; 44:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/29\">",
"      Varlotto JM, Flickinger JC, Kondziolka D, et al. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002; 54:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/30\">",
"      Cavazzuti V, Fischer EG, Welch K, et al. Neurological and psychophysiological sequelae following different treatments of craniopharyngioma in children. J Neurosurg 1983; 59:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/31\">",
"      McMurry FG, Hardy RW Jr, Dohn DF, et al. Long term results in the management of craniopharyngiomas. Neurosurgery 1977; 1:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/32\">",
"      Ignelzi RJ, Squire LR. Recovery from anterograde and retrograde amnesia after percutaneous drainage of a cystic craniopharyngioma. J Neurol Neurosurg Psychiatry 1976; 39:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/33\">",
"      Gutin PH, Klemme WM, Lagger RL, et al. Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system. J Neurosurg 1980; 52:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/34\">",
"      Manaka S, Teramoto A, Takakura K. The efficacy of radiotherapy for craniopharyngioma. J Neurosurg 1985; 62:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/35\">",
"      Huk WJ, Mahlstedt J. Intracystic radiotherapy (90Y) of craniopharyngiomas: CT-guided stereotaxic implantation of indwelling drainage system. AJNR Am J Neuroradiol 1983; 4:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/36\">",
"      Julow J, L&aacute;nyi F, Hajda M, et al. The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid. Acta Neurochir (Wien) 1985; 74:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/37\">",
"      Voges J, Sturm V, Lehrke R, et al. Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 1997; 40:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/38\">",
"      Pollock BE, Lunsford LD, Kondziolka D, et al. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. Int J Radiat Oncol Biol Phys 1995; 33:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/39\">",
"      Backlund EO, Johansson L, Sarby B. Studies on craniopharyngiomas. II. Treatment by stereotaxis and radiosurgery. Acta Chir Scand 1972; 138:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/40\">",
"      Van den Berge JH, Blaauw G, Breeman WA, et al. Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg 1992; 77:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/41\">",
"      Barriger RB, Chang A, Lo SS, et al. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011; 98:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/42\">",
"      Fang Y, Cai BW, Zhang H, et al. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 2012; 4:CD008890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/43\">",
"      Hukin J, Steinbok P, Lafay-Cousin L, et al. Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 2007; 109:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/44\">",
"      Shi XE, Wu B, Fan T, et al. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008; 110:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/45\">",
"      Elliott RE, Hsieh K, Hochm T, et al. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr 2010; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/46\">",
"      Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004; 58:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/47\">",
"      Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/48\">",
"      Lin LL, El Naqa I, Leonard JR, et al. Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr 2008; 1:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/49\">",
"      Mark RJ, Lutge WR, Shimizu KT, et al. Craniopharyngioma: treatment in the CT and MR imaging era. Radiology 1995; 197:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/50\">",
"      Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 1999; 90:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/51\">",
"      Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999; 90:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/52\">",
"      M&uuml;ller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst 2005; 21:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/53\">",
"      Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/54\">",
"      Lipton J, Megerian JT, Kothare SV, et al. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology 2009; 73:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/55\">",
"      van der Klaauw AA, Biermasz NR, Pereira AM, et al. Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clin Endocrinol (Oxf) 2008; 69:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/56\">",
"      Dolson EP, Conklin HM, Li C, et al. Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer 2009; 52:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/57\">",
"      Liu AK, Bagrosky B, Fenton LZ, et al. Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer 2009; 52:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/58\">",
"      Enchev Y, Ferdinandov D, Kounin G, et al. Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature. Clin Neurol Neurosurg 2009; 111:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/59\">",
"      Lermen O, Frank S, Hassler W. Postoperative spinal recurrence of craniopharyngioma. Acta Neurochir (Wien) 2010; 152:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/60\">",
"      Elliott RE, Moshel YA, Wisoff JH. Surgical treatment of ectopic recurrence of craniopharyngioma. Report of 4 cases. J Neurosurg Pediatr 2009; 4:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/61\">",
"      Frangou EM, Tynan JR, Robinson CA, et al. Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst 2009; 25:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/62\">",
"      Romani R, Niemel&auml; M, Celik O, et al. Ectopic recurrence of craniopharyngioma along the surgical route: case report and literature review. Acta Neurochir (Wien) 2010; 152:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24520/abstract/63\">",
"      Visser J, Hukin J, Sargent M, et al. Late mortality in pediatric patients with craniopharyngioma. J Neurooncol 2010; 100:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5210 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24520=[""].join("\n");
var outline_f23_60_24520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - RT techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cyst management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Intracavitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intracavitary chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disease control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endocrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Neurologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Visual",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Vascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Secondary malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      POST TREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H985761160\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5210|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/50/35631\" title=\"diagnostic image 1\">",
"      Craniopharyngioma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/25/29074\" title=\"diagnostic image 2A\">",
"      Craniopharyngioma MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/37/39507\" title=\"diagnostic image 2B\">",
"      Craniopharyngioma MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/59/38847\" title=\"diagnostic image 3\">",
"      Craniopharyngioma Plain film",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24521="Approach to the infant or child with nausea and vomiting";
var content_f23_60_24521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the infant or child with nausea and vomiting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24521/contributors\">",
"     Carlo Di Lorenzo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24521/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24521/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/60/24521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are common sequelae of a multitude of disorders that can range from mild, self-limited illnesses to severe, life-threatening conditions. Nausea generally refers to an unmistakable sensation of unpleasantness that may precede vomiting, but may be present even in a child who does not vomit. It is often associated with autonomic changes such as salivation, increased heart and respiratory rates, and a reduction in gastric tone and mucosal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although there is no forceful expulsion of gastric contents with nausea, there may be retrograde reflux of fluids from the duodenum to the antrum.",
"   </p>",
"   <p>",
"    Vomiting refers to the forceful oral expulsion of gastric contents associated with contraction of the abdominal and chest wall musculature (",
"    <a class=\"graphic graphic_table graphicRef55952 \" href=\"UTD.htm?39/42/40619\">",
"     table 1",
"    </a>",
"    ). It may have a physiologic benefit since it provides a means to expel potential toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/3\">",
"     3",
"    </a>",
"    ]. Vomitus often has a slight yellow tinge, which is caused by reflux of small amounts of bile into the stomach. Vomitus is considered bilious if it has a green or bright yellow color, indicating larger amounts of bile in the stomach; bilious vomiting is often associated with intestinal obstruction, as described below. &nbsp;",
"   </p>",
"   <p>",
"    Nausea and vomiting often are not perceived at the same level of intensity. As an example, vomiting can occur without preceding nausea in individuals with mass lesions in the brain or increased intracranial pressure. Furthermore, some medications may alleviate nausea but not vomiting or vice versa.",
"   </p>",
"   <p>",
"    A standardized approach to children with nausea and vomiting cannot be recommended because these symptoms may be caused by many pathologic states involving several systems (including gastrointestinal, neurologic, renal, and psychiatric). Younger children may not be able to describe nausea, which may further complicate diagnosis. The best course of action should be dictated by the medical history, taking into consideration clinical features of specific disorders and their relative frequency among children in different age groups. The most important consideration during the initial encounter is recognition of serious conditions (such as intestinal obstruction and increased intracranial pressure) for which immediate intervention is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the neurophysiology and differential diagnosis of nausea and vomiting in children, while suggesting a general approach to specific testing. Individual disorders are discussed in further detail on the corresponding topic reviews. Several gastrointestinal disorders present with abdominal pain in addition to nausea and vomiting, and these are discussed below. However, evaluation of the child in whom abdominal pain is the primary presenting complaint is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"     \"Emergent evaluation of the child with acute abdominal pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROPHYSIOLOGY OF EMESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are innate responses that induce a learned and conditioned aversion to ingested toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/3\">",
"     3",
"    </a>",
"    ]. In disease states, however, vomiting pathways are activated inappropriately. There are four major pathways by which nausea and vomiting are induced. These include the [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vagal afferents",
"     </li>",
"     <li>",
"      Area postrema",
"     </li>",
"     <li>",
"      Vestibular system",
"     </li>",
"     <li>",
"      Amygdala",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A basic understanding of these pathways is important to achieve appropriate treatment strategies for nausea and vomiting in the child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vagal afferent pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal vagal afferents are involved in the emetic response. These pathways can be evoked by either mechanical or chemo-sensory sensations. Examples of sensations that trigger this pathway include overdistension, food poisoning, mucosal irritation, cytotoxic drugs, and radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Area postrema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The area postrema has been referred to as the \"chemoreceptor trigger zone.\" Anatomically, this region is located at the caudal extremity of the floor of the fourth ventricle. Because the area postrema represents a relatively permeable blood-brain barrier region, it is the place where many, but not all, systemic chemicals act to induce emesis. Ablation studies have shown that this area contains receptors for neuroactive compounds such as dopamine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    , acetylcholine, endorphin, and many others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vestibular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vestibular system is involved in the emetic response to motion. This response is often exacerbated when vestibular input is in conflict with visual sensations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/3\">",
"     3",
"    </a>",
"    ]. Irritation or labyrinthine inflammation can produce vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/3\">",
"     3",
"    </a>",
"    ]. Others have suggested that over-stimulation of the vestibular system is not a complete explanation for motion sickness. In animal studies, the area postrema appears to play a role in motion sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/4\">",
"     4",
"    </a>",
"    ]. This suggests that circulating neuroactive compounds may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10968566\">",
"    <span class=\"h2\">",
"     Amygdala",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amygdala is involved in a variety of stress and emotional responses. Among other structures, it receives input from the olfactory bulb and olfactory cortex and sends impulses to the hypothalamus. Aberrant activation of the amygdala may lead to a sensation of nausea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOMATOMOTOR EVENTS OF VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The act of vomiting represents a highly coordinated sequence of events. As noted above, vomiting describes the act of emptying out the stomach, characterized by cycles of retching followed by the forceful expulsion of gastric contents. The detailed sequence of events is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diaphragm descends and the intercostal muscles contract while the glottis is closed",
"     </li>",
"     <li>",
"      The abdominal muscles contract and the gastric contents are forced into upper gastric vault and lower esophagus",
"     </li>",
"     <li>",
"      The abdominal muscle relaxes and the esophageal refluxate empties back into the gastric vault",
"     </li>",
"     <li>",
"      Several cycles of retching, each more rhythmical and forceful in nature, occur, with shorter intervals in between",
"     </li>",
"     <li>",
"      Abdominal contraction associated with elevation of diaphragms results in forceful expulsion of gastric contents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS BY AGE GROUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of vomiting is age dependent. The following sections will summarize the clinical features of the relatively common disorders and the less common but serious disorders in various age groups. Many of these disorders present in several age ranges, but are discussed where they present most frequently (",
"    <a class=\"graphic graphic_table graphicRef51919 \" href=\"UTD.htm?0/51/830\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEONATES AND YOUNG INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forceful and repeated vomiting in newborns is not normal and should be taken seriously, particularly if there are other signs of illness (eg, fever, weight loss, or feeding refusal). The most frequent diagnostic considerations in newborns and young infants are gastroesophageal reflux, pyloric stenosis, and intestinal obstruction. Other conditions that may present with vomiting are sepsis, excessive feeding volume, or increased intracranial pressure. Although much less common, inborn errors of metabolism also can present with vomiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic reflux in newborns and infants is common, and is characterized by effortless regurgitation in an otherwise healthy infant (a \"happy spitter\"). This symptom may be described as vomiting by parents. The symptom gradually improves in most infants during the first year of life, and may be minimized by conservative anti-reflux measures.",
"   </p>",
"   <p>",
"    A minority of infants who regurgitate have pathological gastroesophageal reflux, termed gastroesophageal reflux disease (GERD). No features definitively identify these infants, but they may have recurrent fussiness or irritability and feeding aversion. These symptoms are thought to result from pain caused by esophageal acid exposure. Bradycardia or cyanotic episodes also may occur, particularly in preterm or neurologically impaired infants. Poor weight gain despite an adequate intake of calories should prompt evaluation for causes of vomiting and weight loss other than GERD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"     \"Gastroesophageal reflux in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GERD also is an important consideration in older infants, children and adolescents presenting with subacute or chronic nausea or vomiting. The assessment and management of this disorder are discussed in a separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Milk protein induced enteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intolerance of dietary proteins (most commonly milk protein) typically manifest as colitis, presenting with bloody stools. However, in some infants the dietary protein causes an enteritis, with or without associated colitis, and affected infants may present with vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pyloric stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile hypertrophic pyloric stenosis (IHPS) is a condition of hypertrophy of the pylorus, with elongation and thickening, eventually progressing to near-complete obstruction, of the gastric outlet. It occurs in approximately 3 in 1,000 live births, more commonly in males (4:1 to 6:1). Approximately 30 percent of cases occur in firstborn children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"     \"Infantile hypertrophic pyloric stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic presentation of IHPS is the three- to six-week-old baby who develops immediate postprandial, non-bilious, often projectile vomiting and demands to be re-fed soon afterwards (a \"hungry vomiter\"). In the past, patients were classically described as being emaciated and dehydrated with a palpable \"olive-like\" mass at the lateral edge of the rectus abdominus muscle in the right upper quadrant of the abdomen. Laboratory evaluation classically showed a hypochloremic, metabolic alkalosis resulting from the loss of large amounts of gastric hydrochloric acid, the severity of which depended upon the duration of symptoms prior to initial evaluation.",
"   </p>",
"   <p>",
"    The typical presentation has changed over time. Infants are diagnosed earlier, tend to be better nourished, and generally present without significant electrolyte imbalances. The diagnosis is made by ultrasound examination of the abdomen (",
"    <a class=\"graphic graphic_table graphicRef73955 \" href=\"UTD.htm?22/6/22637\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"     \"Infantile hypertrophic pyloric stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants presenting with symptoms similar to those of pyloric stenosis, but with hyperkalemic acidosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disproportionate hypotension, should raise concern for adrenal crisis. This is a life-threatening condition and should be evaluated and treated urgently.",
"   </p>",
"   <p>",
"    The most common cause of adrenal insufficiency in infants is congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In the United States, 21-hydroxylase deficiency is part of the newborn screen in most states, so most such infants will be diagnosed prior to developing adrenal crisis. Adrenal crisis usually presents between the first and fourth week of life. Affected females will have ambiguous genitalia; males usually have no obvious genital abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Adrenal crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of intestinal obstruction in neonates and young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Causes of intestinal obstruction that present during early infancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malrotation with or without volvulus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=see_link\">",
"       \"Intestinal malrotation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hirschsprung disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intussusception (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Intussusception'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"       \"Intussusception in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intestinal atresia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31608?source=see_link\">",
"       \"Intestinal atresia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyloric stenosis (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Pyloric stenosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intestinal obstruction frequently causes bile staining in the vomitus. Bile-stained vomitus should be treated as a life-threatening emergency, although it can be seen occasionally in infants without bowel obstruction. Vomiting that is not bile-stained may be caused by proximal obstruction, such as pyloric stenosis, upper duodenal stenosis, gastric volvulus, or annular pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If intestinal obstruction is suspected, the specific diagnosis often can be suggested by the patient's history and with appropriate radiologic imaging. Plain radiographs of the abdomen generally provide a rapid assessment of possible bowel obstruction with relatively little radiation exposure (",
"    <a class=\"graphic graphic_table graphicRef73955 \" href=\"UTD.htm?22/6/22637\">",
"     table 3",
"    </a>",
"    ). Abdominal ultrasound provides high sensitivity and specificity for detecting intussusception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Malrotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malrotation is an anomaly of fetal intestinal development that occurs in about 1 in 6000 newborns. In this condition, the cecum is abnormally positioned in the right upper quadrant, and is fixated to the right lateral abdominal wall by bands of peritoneum. These abnormalities predispose to intestinal volvulus, in which the intestine twists on its mesentery. This causes acute small bowel obstruction and ischemia, which usually presents with sudden onset of bilious vomiting and an acute abdomen. Volvulus occurs early in infancy in approximately half of infants with malrotation. Other infants with malrotation may remain asymptomatic, or present later in childhood with volvulus. Affected infants also may present with signs of duodenal obstruction, or with associated congenital anomalies such as intestinal atresias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=see_link\">",
"     \"Intestinal malrotation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Hirschsprung disease are diagnosed in the neonatal period. Patients present with symptoms of distal intestinal obstruction: bilious emesis, abdominal distension, and failure to pass stool. The diagnosis can be suggested by a delay in passage of the first meconium (greater than 48 hours of age). Affected children may also present initially with enterocolitis, a potentially life threatening illness in which patients have a sepsis-like picture with fever, vomiting, diarrhea, and abdominal distension, which can progress to toxic megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inborn errors of metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inborn errors of metabolism are rare causes of vomiting in neonates and young infants. Nonetheless, recognition of these disorders is important because the institution of appropriate therapy can be life-saving. The clinical presentation varies with the type of metabolic disorder. Recurrent episodes of vomiting and dehydration generally are associated with the organic acidemias and urea cycle disorders. The typical presentation of urea cycle disorders or organic acidemias in newborns is an acute, severe illness characterized by lethargy, poor feeding, vomiting, and shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OLDER INFANTS AND CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple disorders may present with vomiting in older infants and children. By far, the most common is gastroenteritis. However, gastroesophageal reflux disease (GERD), gastroparesis, mechanical obstruction, anaphylaxis, Munchausen syndrome by proxy (factitious disorder by proxy), intracranial masses, peptic ulcer disease, cyclic vomiting and diabetic ketoacidosis also may be diagnostic considerations. Adrenal crisis and anaphylaxis should be considered in children with disproportionate hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    predisposing factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenteritis usually is viral in etiology, occurring in epidemics, sudden in onset and quick to resolve. Bacterial causes may be associated with more prolonged and severe illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastroparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroparesis is the condition of impaired emptying of gastric contents into the duodenum in the absence of a mechanical obstruction; this may cause postprandial vomiting. In gastroparesis the vomiting usually occurs many hours after ingestion of food, a characteristic that differentiates this entity from GER or rumination syndrome, in which the emesis is during or immediately after eating.",
"   </p>",
"   <p>",
"    The following conditions may cause gastroparesis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgery with vagus nerve damage (eg, fundoplication)",
"     </li>",
"     <li>",
"      Use of drugs such as opioids or anticholinergics",
"     </li>",
"     <li>",
"      Metabolic disturbances such as hypokalemia, acidosis, or hypothyroidism",
"     </li>",
"     <li>",
"      Eosinophilic gastroenteropathy",
"     </li>",
"     <li>",
"      Neuromuscular disorders such as cerebral palsy, diabetes mellitus, pseudo-obstruction and muscular dystrophy",
"     </li>",
"     <li>",
"      Viral illness (postviral gastroparesis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postviral gastroparesis is often found in children who have experienced a short viral illness (often rotavirus gastroenteritis) and is associated with postprandial antral hypomotility. In most cases, the symptoms resolve spontaneously within 6 to 24 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intussusception is the most common cause of intestinal obstruction in infants between 6 and 36 months of age. Patients with intussusception typically develop the sudden onset of intermittent, severe, crampy, progressive abdominal pain, accompanied by inconsolable crying and drawing up of the legs toward the abdomen. The episodes become more frequent and more severe over time. Vomiting may follow episodes of abdominal pain. Initially emesis is non-bilious, but it may become bilious as the obstruction progresses. A sausage-shaped abdominal mass may be felt in the right side of abdomen. As symptoms progress, increasing lethargy develops, which can be mistaken for meningoencephalitis. In up to 70 percent of cases, the stool contains gross or occult blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intussusception also can occur in neonates and young infants. In infants, intussusception may present as lethargy, with or without vomiting or rectal bleeding. In young infants, intussusception is more often caused by a pathological lead point, such as Meckel diverticulum or a duplication cyst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis, triggered by ingested items (typically foods or medications), tends to present with prominent gastrointestinal symptoms, including nausea, crampy or colicky abdominal pain, vomiting (sometimes large quantities of \"stringy\" mucus), and diarrhea.",
"   </p>",
"   <p>",
"    During anaphylaxis, gastrointestinal symptoms are accompanied by various signs and symptoms involving the skin and mucosa tissue, respiratory tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular system. These include pruritus, flushing,",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    periorbital edema, conjunctival injection, rhinorrhea, nasal congestion, cough, wheezing, dyspnea, change of voice quality, sense of choking, tachycardia (or bradycardia less commonly), dizziness, hypotension, sense of impending doom, and cardiovascular collapse. The diagnosis and treatment of anaphylaxis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngitis (particularly streptococcal pharyngitis) and urinary tract infections frequently present with nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adrenal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is uncommon, adrenal crisis should be considered in children of any age, particularly if they have risk factors (such as known adrenal insufficiency or history of corticosteroid use),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    present with disproportionate hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperkalemic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Adrenal crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumors and other intracranial masses can cause nausea, vomiting, or both, by increasing the intracranial pressure at the area postrema of the medulla. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several characteristics suggest the possibility of tumor-associated emesis, such as triggering emesis by an abrupt change in body position. More importantly, neurogenic nausea and vomiting usually occurs in the context of other neurologic symptoms such as headache or focal neurologic deficit; these signs and symptoms may be subtle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Idiopathic intracranial hypertension refers to increased intracranial pressure (ICP) with normal cerebrospinal fluid (CSF) content, normal neuroimaging, the absence of neurologic signs except cranial nerve VI palsy, and no known cause. The clinical manifestations of idiopathic intracranial hypertension vary with age; younger children, for example, who cannot complain of headache or visual impairment, may present with irritability, sleep, or behavior disturbance. In comparison, headache is a more common chief complaint in older children and frequently is described as being pulsatile, occasionally awakening the child from sleep. Associated nausea or vomiting may be present, as may neck or retroocular pain that is worse with eye movement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cyclic vomiting syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic vomiting syndrome is a disorder characterized by repeated episodes of nausea and vomiting that last for hours to days separated by symptom-free periods of variable length. This on-off pattern of emesis is quite distinct from most other causes of vomiting. Intense vomiting and nausea are the cardinal symptoms and usually lead to significant deficits of fluids and electrolytes. Cyclic vomiting has been most often described in school-aged children, but may affect other age groups. The etiology is unknown, although many hypotheses have been proposed. An association between cyclic vomiting syndrome and migraine headaches has been most consistently described, suggesting that there may be a common pathophysiologic process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link\">",
"     \"Cyclic vomiting syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10968558\">",
"    <span class=\"h2\">",
"     Eosinophilic esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic esophagitis is an inflammatory condition that can affect the esophageal mucosa at any age but is most common in school-aged children and adolescents. Its prevalence seems to have increased during the past 10 to 15 years. It is characterized by an eosinophilic mucosal infiltrate throughout the entire esophagus and is more common in children with other allergic disorders, such as eczema and asthma; it often is a manifestation of food allergy. Symptoms vary by age, with adolescents and adults usually presenting with dysphagia and younger children more likely to have pain, nausea, vomiting, or feeding difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Munchausen syndrome by proxy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Munchausen syndrome by proxy (also known as factitious disorder by proxy, Meadow syndrome, and proxy factitia) consists of fabricating or inducing illness in a child in order to get attention. The patient may have a history of frequent recurrent illnesses without a clear etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis should be considered if the following features are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reported history varies from what is observed or does not make sense",
"     </li>",
"     <li>",
"      The illness is unexplained, unusual, or prolonged and does not respond to treatment as expected",
"     </li>",
"     <li>",
"      The problem seems to originate only in the presence of the suspected perpetrator",
"     </li>",
"     <li>",
"      The problem resolves or improves when the child is separated from the suspected perpetrator",
"     </li>",
"     <li>",
"      The problem recurs when the suspected perpetrator is told that the child is improving or is soon to be released from the hospital or treatment program",
"     </li>",
"     <li>",
"      Family members have unexplained symptoms, illness, or death",
"     </li>",
"     <li>",
"      The suspected perpetrator behaves in a manner that appears to be consistent with exaggeration, fabrication, or induction of physical, psychological, or behavioral problems in the child",
"     </li>",
"     <li>",
"      The alleged perpetrator does not seem to be as worried by the child's illness as the health professionals who are caring for the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the disorders affecting children listed above, some of the more common causes of nausea and vomiting in adolescents include gastroenteritis, appendicitis, inflammatory bowel disease, pregnancy, and toxic ingestions. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Older infants and children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspepsia is defined by a persistent or recurrent pain or discomfort localized to the upper abdomen; it is often associated with postprandial nausea, vomiting, and early fullness. Dyspepsia may occasionally arise from an organic disease such as peptic ulcer (with or without underlying Helicobacter pylori infection), allergy, or Crohn disease. However, in most cases dyspepsia appears to be functional in nature, due to a disorder of upper gastrointestinal sensation and motility [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/10\">",
"     10",
"    </a>",
"    ]. The approach to the adolescent patient with dyspeptic symptoms, and a more detailed discussion of functional dyspepsia are given separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicitis presents most frequently in the second decade of life, and is the most common indication for emergent abdominal surgery in childhood.",
"   </p>",
"   <p>",
"    Early signs and symptoms of appendicitis are often subtle, and may vary depending upon the location of the appendix. An inflamed anterior or pelvic appendix produces marked symptoms in the right lower quadrant, while a retrocecal appendix may not cause the same degree of local signs of peritonitis because the inflammation is masked by the overlying bowel.",
"   </p>",
"   <p>",
"    In many patients, initial features are nonspecific, including indigestion, flatulence, bowel irregularity, and sometimes just a sense of not feeling well. These symptoms usually are followed by pain in the epigastrium or periumbilical region, which is visceral in character (ie, constant, not very severe in intensity, and poorly localizable). The symptoms eventually localize to the right lower quadrant once inflammation involves the overlying parietal peritoneum. Nausea and vomiting, if they occur, follow the onset of pain. The diagnosis of appendicitis is less likely in patients in whom nausea and emesis are the first signs of illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although inflammatory bowel disease (ulcerative colitis and Crohn disease) may present with complaints of nausea, frank vomiting is rarely a primary presenting symptom. The disease should be considered if there are suggestive features in the history and clinical presentation (especially growth failure, anemia, abdominal pain, perianal disease, bloody diarrhea, or arthritis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatricians should have a low threshold for suspecting pregnancy in adolescents. Adolescents may or may not have considered the possibility of pregnancy or may present with vague complaints with suspected pregnancy as her \"hidden agenda.\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=see_link&amp;anchor=H3#H3\">",
"     \"Pregnancy in adolescents\", section on 'Diagnosis of pregnancy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Bulimia or psychogenic vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulimia nervosa should be considered in a patient with concerns about body weight and shape. Psychogenic vomiting is more likely in a patient with an anxiety disorder, or may coincide with particularly stressful situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Adolescent rumination syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rumination syndrome, characterized by effortless regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    re-swallowing of food, has previously been recognized as a disorder of emotionally deprived infants. More recently it was recognized as a problem of older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/11\">",
"     11",
"    </a>",
"    ]. Some patient groups, such as adolescent girls, are at higher risk of rumination syndrome. It has been suggested that this condition may be considered a form fruste of an eating disorder. The severity of adolescent rumination syndrome varies, ranging from a benign disorder, amenable to behavioral therapies, to much more severe forms interfering with the ability to work or attend school.",
"   </p>",
"   <p>",
"    The characteristic of this condition is the presence of regurgitation without nausea immediately after eating. The symptoms disappear hours after eating once the regurgitated material becomes acidic, and do not occur during sleep. The clinical characteristics and diagnosis of rumination syndrome are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Rumination syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, vomiting is a common feature of many diseases (",
"    <a class=\"graphic graphic_table graphicRef58813 \" href=\"UTD.htm?30/31/31229\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53115 \" href=\"UTD.htm?3/25/3485\">",
"     table 5",
"    </a>",
"    ). A detailed history and astute clinical acumen are necessary to narrow down the diagnostic possibilities. The appropriate urgency with which various diagnostic modalities should be pursued depends upon a number of factors, including the duration of illness, overall clinical status of the patient (especially hydration, circulatory, and neurologic status) and associated findings on the physical examination and history.",
"   </p>",
"   <p>",
"    Prolonged vomiting (&gt;12 hours in a neonate, &gt;24 hours in children younger than two years of age, or &gt;48 hours in older children) should not be ignored. Screening laboratory tests should include a complete blood count, electrolytes, glucose, blood urea nitrogen, amylase, lipase, liver function tests, urinalysis, urine culture, and stool studies for occult blood, leukocytes, and parasites. Additional testing should be based upon the history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef54450 \" href=\"UTD.htm?9/56/10124\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients should be referred to a pediatric gastroenterologist or other appropriate specialist (eg, pediatric surgeon, neurologist) when there are symptoms or physical findings that are of particular concern. These include an abnormal neurologic exam, peritoneal signs on abdominal examination, severe abdominal pain, gastrointestinal bleeding, or significant weight loss. Immediate pediatric surgical consultation is warranted if appendicitis, bowel obstruction, or bowel perforation are suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Clues on physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain physical findings may offer diagnostic clues that can aid in narrowing the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef53115 \" href=\"UTD.htm?3/25/3485\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tense, bulging fontanelle in a neonate or young infant should increase the level of suspicion for meningitis",
"     </li>",
"     <li>",
"      Projectile vomiting in an infant three to six weeks of age suggests pyloric stenosis as a diagnosis (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Pyloric stenosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ambiguous genitalia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperkalemia suggest the possibility of adrenal crisis (usually due to congenital adrenal hyperplasia), (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Adrenal insufficiency'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Headache, positional triggers for vomiting, lack of nausea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting on awakening should suggest the possibility of intracranial hypertension (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Intracranial hypertension'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      An unusual odor emanating from the patient should prompt an investigation for metabolic causes of vomiting (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Inborn errors of metabolism'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Marked distension, visible bowel loops, absent bowel sounds, green or yellow bile, or increased \"rumbling\" bowel sounds (\"borborygmi\") should raise suspicion for intestinal obstruction (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Intestinal obstruction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Enlarged parotid glands in an adolescent should raise suspicion for bulimia (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Bulimia or psychogenic vomiting'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Vomiting in association with trauma should prompt imaging studies to rule out intracranial or intraabdominal injury.",
"     </li>",
"     <li>",
"      Hypotension disproportionate to the apparent illness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperkalemia suggests the possibility of adrenal crisis (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Adrenal crisis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be directed toward the underlying etiology. Electrolyte abnormalities, metabolic abnormalities, or nutritional deficiencies should be corrected. Cognitive-behavioral interventions are useful for vomiting associated with functional dyspepsia, adolescent rumination syndrome, and bulimia. Prokinetic medications such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    (where available), and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    are beneficial when there are clear abnormalities in esophago-gastric motility, but generally are not indicated for gastroesophageal reflux disease. The United States Food and Drug Administration (FDA) has issued a &ldquo;boxed warning&rdquo; about the potential for tardive dyskinesia associated with chronic or high dose use of metoclopramide. Hence, this drug should be used only after a careful discussion with the patient and the caretakers about its possible risks and benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Prokinetics'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Antiemetics, which are useful in persistent vomiting to avoid electrolyte abnormalities or nutritional sequelae, typically have not been recommended in the case of vomiting of unknown etiology (",
"    <a class=\"graphic graphic_table graphicRef60807 \" href=\"UTD.htm?8/50/9005\">",
"     table 7",
"    </a>",
"    ). These agents are contraindicated in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/1\">",
"     1",
"    </a>",
"    ]. Likewise, they are not indicated for anatomic abnormalities or surgical abdomen. Instead, antiemetics are most useful for motion sickness, postoperative vomiting, cyclic vomiting syndrome, and gastrointestinal motility disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, a double-blind study suggests that single dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    may facilitate oral rehydration in children with gastroenteritis who are unable to tolerate oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link&amp;anchor=H19#H19\">",
"     \"Oral rehydration therapy\", section on 'Vomiting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the last two decades, there have been considerable advances in the development of antiemetics. These include the emergence of 5-hydroxytryptamine 3 receptor antagonists (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     Ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/36/33349?source=see_link\">",
"     Granisetron",
"    </a>",
"    ), which have one primary site of antagonism and have helped in the treatment of post-operative nausea and vomiting and chemotherapy-associated emesis. Other antiemetics are in development, which have a broader spectrum of effects. These include neurokinin 1 receptor antagonists that likely mediate nausea and vomiting triggered by chemotherapeutic agents, motion, gastric irritants, and other stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients and families are increasingly turning to complementary and alternative medicine for a variety of complaints, particularly if the symptom is chronic or does not have a clear diagnostic explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/14\">",
"     14",
"    </a>",
"    ]. Applications of these techniques to the symptoms of nausea and vomiting have not been well studied, but there is some evidence for efficacy of some nutraceuticals, such as ginger and other herbal compounds for functional dyspepsia and other motility disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ]. Hypnotherapy is often helpful for treatment of anticipatory nausea and vomiting (eg, prior to chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/17\">",
"     17",
"    </a>",
"    ]; studies of hypnotherapy for functional dyspepsia are less conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24521/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The definitions and general approaches of other complementary and alternative techniques are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=see_link\">",
"     \"Overview of complementary and alternative medicine in pediatrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/27/26033?source=see_link\">",
"       \"Patient information: Pyloric stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       \"Patient information: Nausea and vomiting in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of nausea and vomiting may be caused by a wide range of conditions, affecting several different organ systems, with vastly different health implications. The immediate goal of the evaluation is to recognize serious conditions for which immediate intervention is required, then to identify a specific cause of the symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes of vomiting vary by age. Many of these disorders present in several age ranges, but may be grouped into age ranges in which they present most frequently (",
"      <a class=\"graphic graphic_table graphicRef51919 \" href=\"UTD.htm?0/51/830\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis by age group'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged vomiting (&gt;12 hours in a neonate, &gt;24 hours in children younger than two years of age, or &gt;48 hours in older children) should not be ignored. Laboratory testing should be performed to screen for causes of the symptom, guided by the history and physical examination (",
"      <a class=\"graphic graphic_table graphicRef54450 \" href=\"UTD.htm?9/56/10124\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Concerning signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination provides important clues to disorders requiring urgent intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked distension, visible bowel loops, absent bowel sounds, green or yellow bile, or increased \"rumbling\" bowel sounds (\"borborygmi\") should raise suspicion for intestinal obstruction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intestinal obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intussusception is the most common cause of intestinal obstruction in infants between 6 and 36 months of age, and typically presents with sudden onset of intermittent, severe, crampy, progressive abdominal pain. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intussusception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Headache, positional triggers for vomiting, lack of nausea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting on awakening should suggest the possibility of intracranial hypertension. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Intracranial hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypotension disproportionate to the apparent illness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperkalemia suggests the possibility of adrenal crisis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Adrenal crisis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Verma R. Vomiting. In: Clinical Pediatric Gastroenterology, Altschuler SM, Liacouras CA (Eds), Churchill Livingstone, Philadelphia 1998. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/2\">",
"      Lang IM. Digestive tract motor correlates of vomiting and nausea. Can J Physiol Pharmacol 1990; 68:242.",
"     </a>",
"    </li>",
"    <li>",
"     Sondheimer JM. Vomiting. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario 2004. p.203.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/4\">",
"      Ito S, Tamura K, Nagae I, et al. Ultrasonographic diagnosis criteria using scoring for hypertrophic pyloric stenosis. J Pediatr Surg 2000; 35:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/5\">",
"      Janik JS, Ein SH, Filler RM, et al. An assessment of the surgical treatment of adhesive small bowel obstruction in infants and children. J Pediatr Surg 1981; 16:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/6\">",
"      Jabra AA, Fishman EK. Small bowel obstruction in the pediatric patient: CT evaluation. Abdom Imaging 1997; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/7\">",
"      Ikeda H, Matsuyama S, Suzuki N, et al. Small bowel obstruction in children: review of 10 years experience. Acta Paediatr Jpn 1993; 35:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/8\">",
"      Cribbs RK, Gow KW, Wulkan ML. Gastric volvulus in infants and children. Pediatrics 2008; 122:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/9\">",
"      Aceves SS, Newbury RO, Dohil MA, et al. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann Allergy Asthma Immunol 2009; 103:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/10\">",
"      Perez ME, Youssef NN. Dyspepsia in childhood and adolescence: insights and treatment considerations. Curr Gastroenterol Rep 2007; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/11\">",
"      Chial HJ, Camilleri M, Williams DE, et al. Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics 2003; 111:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/12\">",
"      Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 2006; 354:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/13\">",
"      Loewen PS. Anti-emetics in development. Expert Opin Investig Drugs 2002; 11:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/14\">",
"      Vlieger AM, Blink M, Tromp E, Benninga MA. Use of complementary and alternative medicine by pediatric patients with functional and organic gastrointestinal diseases: results from a multicenter survey. Pediatrics 2008; 122:e446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/15\">",
"      Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005; 50:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/16\">",
"      von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/17\">",
"      Marchioro G, Azzarello G, Viviani F, et al. Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology 2000; 59:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/18\">",
"      Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/19\">",
"      Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24521/abstract/20\">",
"      Chiarioni G, Vantini I, De Iorio F, Benini L. Prokinetic effect of gut-oriented hypnosis on gastric emptying. Aliment Pharmacol Ther 2006; 23:1241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5902 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24521=[""].join("\n");
var outline_f23_60_24521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROPHYSIOLOGY OF EMESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vagal afferent pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Area postrema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vestibular system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10968566\">",
"      Amygdala",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOMATOMOTOR EVENTS OF VOMITING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS BY AGE GROUP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEONATES AND YOUNG INFANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Milk protein induced enteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Malrotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OLDER INFANTS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intussusception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adrenal crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10968558\">",
"      Eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Munchausen syndrome by proxy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Bulimia or psychogenic vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Adolescent rumination syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Clues on physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Concerning signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/42/40619\" title=\"table 1\">",
"      Nausea vomiting terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/51/830\" title=\"table 2\">",
"      Dx vomiting children by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/6/22637\" title=\"table 3\">",
"      Imaging options for vomiting infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/31/31229\" title=\"table 4\">",
"      Dx vomiting children by system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/25/3485\" title=\"table 5\">",
"      Clin features vomiting children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/56/10124\" title=\"table 6\">",
"      Vomiting dx studies children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/50/9005\" title=\"table 7\">",
"      Antiemetic drugs children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=related_link\">",
"      Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31608?source=related_link\">",
"      Intestinal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/27/26033?source=related_link\">",
"      Patient information: Pyloric stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=related_link\">",
"      Pregnancy in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24522="Overview of benign bone tumors in children and adolescents";
var content_f23_60_24522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of benign bone tumors in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24522/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24522/contributors\">",
"     John E Tis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24522/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/60/24522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/60/24522/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/60/24522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign childhood bone tumors range from static lesions, such as nonossifying fibromas, which remain essentially unchanged throughout childhood, to locally aggressive lesions, such as aneurysmal bone cysts, which continue to expand until treated. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Nonossifying fibroma'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Aneurysmal bone cyst'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most benign bone tumors have characteristic radiographic features and can be diagnosed with plain radiographs. It is important to be familiar with the radiographic appearance of the most common benign bone tumors. Benign bone tumors often are discovered incidentally, and recognition of benign lesions on plain radiographs can avoid unnecessary advanced imaging and invasive diagnostic studies.",
"   </p>",
"   <p>",
"    An overview of the presentation, clinical and radiographic features, and management of the most common benign pediatric bone tumors will be presented below. Malignant bone tumors (Ewing sarcoma and osteosarcoma) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign bone tumors often are asymptomatic and discovered incidentally during evaluation for trauma or another condition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ]. When they are symptomatic, benign bone tumors may present with localized pain, swelling, deformity, or pathologic fracture. In most cases, the differential diagnosis of these lesions can be narrowed based upon the age of the child, the involved bone, the location of the lesion within the bone, and other general radiographic characteristics (",
"    <a class=\"graphic graphic_table graphicRef69193 \" href=\"UTD.htm?23/34/24110\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain aspects of the history may be helpful in narrowing the differential diagnosis of a benign-appearing bone tumor. These include (",
"    <a class=\"graphic graphic_table graphicRef69193 \" href=\"UTD.htm?23/34/24110\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ndash; Most benign bone tumors typically present during the second decade. However, ossifying fibroma (osteofibrous dysplasia) typically presents in the first five years of life, and Langerhans cell histiocytosis of bone presents in the first decade of life.",
"     </li>",
"     <li>",
"      Pain &ndash; Pain that quickly resolves (within 20 to 25 minutes) with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      or other nonsteroidal antiinflammatory medications is characteristic of osteoid osteoma. Nonaggressive benign bone tumors (eg, unicameral bone cyst, nonossifying fibroma) usually are asymptomatic but may cause pain in association with pathologic fracture, bursa formation, or neurovascular compression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"       1",
"      </a>",
"      ]. Aggressive benign bone tumors (eg, aneurysmal bone cyst, chondroblastoma, chondromyxoid fibroma) may cause pain that is mild, dull, slowly progressive, and worse at night [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"       3",
"      </a>",
"      ]. The pain associated with malignant bone tumors may awaken the child from sleep but is more rapidly progressive than the pain of aggressive benign bone tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic symptoms &ndash; Associated systemic symptoms (eg, fever, malaise) may indicate an underlying generalized disorder or osteomyelitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the examination in a child with a bone tumor include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth parameters &ndash; Patients with hereditary multiple osteochondromas may have short stature.",
"     </li>",
"     <li>",
"      Head, eyes, ears, nose, and throat &ndash; Signs of",
"      <span class=\"nowrap\">",
"       chronic/refractory",
"      </span>",
"      otitis media (eg, scarring of the tympanic membrane) and proptosis may indicate Langerhans cell histiocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"       \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Musculoskeletal &ndash; During the musculoskeletal examination, it is important to determine the location and size of the lesion(s) and to assess bone tenderness, bone or joint swelling, deformity (patients with hereditary multiple osteochondromas or enchondromas may have angular deformities of the upper or lower extremities), joint range of motion, neurologic function, and vascular function (neurovascular compromise may indicate an aggressive tumor). Osteochondromas and periosteal chondromas may be palpable.",
"     </li>",
"     <li>",
"      Skin &ndash; Caf&eacute;-au-lait macules (",
"      <a class=\"graphic graphic_picture graphicRef80844 \" href=\"UTD.htm?41/51/42815\">",
"       picture 1",
"      </a>",
"      ) may indicate polyostotic fibrous dysplasia (McCune-Albright syndrome) or neurofibromatosis. Soft tissue myxomas may indicate Mazabraud syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/4\">",
"       4",
"      </a>",
"      ]. Hemangiomas may suggest Maffucci syndrome (a subtype of enchondromatosis). Overlying erythema, warmth, and soft tissue swelling may suggest underlying infection (eg, osteomyelitis).",
"     </li>",
"     <li>",
"      Lymph nodes &ndash; Regional lymphadenopathy may indicate infection or a systemic process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collaboration between the clinician and radiologist is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. Most benign bone tumors have characteristic radiographic features and can be diagnosed with plain radiographs. It is important to be familiar with the radiographic appearance of the most common benign bone tumors (",
"    <a class=\"graphic graphic_table graphicRef69193 \" href=\"UTD.htm?23/34/24110\">",
"     table 1",
"    </a>",
"    ). Benign bone tumors often are discovered incidentally, and recognition of benign lesions on plain radiographs may avoid unnecessary advanced imaging (eg, computed tomography, magnetic resonance imaging) and invasive diagnostic studies (eg, biopsy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are the best initial modality for evaluation of primary bone lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The evaluation should include views in two planes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of benign bone tumor can be made with plain radiographs alone in 80 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ]. If the lesion is clearly benign on plain films, cross-sectional imaging should not be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumors of the pelvis or scapula can be difficult to see on plain films. Advanced imaging techniques (eg, computed tomography, magnetic resonance imaging) may be necessary to fully characterize bone tumors in these locations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiographs should be reviewed systematically by considering the following questions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Where is the tumor? (Long bone or flat bone?; epiphysis, metaphysis, or diaphysis?; medulla, cortex, or surface?) (",
"      <a class=\"graphic graphic_figure graphicRef50795 \" href=\"UTD.htm?13/34/13864\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      What is the tumor doing to the bone? Is the tumor destroying or replacing existing bone? If so, what is the pattern?",
"     </li>",
"     <li>",
"      What is the bone doing to the tumor? Is there periosteal or endosteal reaction? If so, is it well-developed? Is it sharply defined? What is the type of periosteal reaction: reinforcing, spiculated, solid, interrupted?",
"     </li>",
"     <li>",
"      Are there intrinsic characteristics that suggest histology? Is there bone formation? Calcification? Is the lesion completely radiolucent?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic characteristics of benign bone lesions include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Well-defined or sclerotic border",
"     </li>",
"     <li>",
"      Sharp zone of transition",
"     </li>",
"     <li>",
"      Small size or multiple lesions",
"     </li>",
"     <li>",
"      Confinement by natural barriers (eg, growth plate, cortex)",
"     </li>",
"     <li>",
"      Lack of destruction of the cortex",
"     </li>",
"     <li>",
"      Lack of extension into the soft tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic characteristics of more aggressive lesions include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor definition",
"     </li>",
"     <li>",
"      Cortical destruction (\"moth-eaten\" or permeative pattern)",
"     </li>",
"     <li>",
"      Spiculated or interrupted periosteal reaction; however, the absence of these findings does not exclude an aggressive lesion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Extension into the soft tissue",
"     </li>",
"     <li>",
"      Large size",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Advanced imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced imaging techniques (computed tomography [CT], magnetic resonance imaging [MRI], scintigraphy) may be necessary for bone lesions that are not clearly benign on plain radiographs. Advanced imaging also may be necessary to detect tumors in the spine, scapula, ribs, or pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT may be helpful in evaluating areas of the body that are difficult to see with plain films (eg, pelvis, scapula, spine) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"     2",
"    </a>",
"    ]. Compared with plain film, CT can better define the location of the lesion within the bone (eg, periosteal, cortex, medullary), more accurately evaluate changes in the cortex (eg, focal destruction or endosteal scalloping), and can detect more subtle matrix mineralization. It also may be helpful in guiding therapy (eg, localization of the nidus in osteoid osteoma). However, the benefit of the supplementary information must be weighed against the additional radiation exposure.",
"   </p>",
"   <p>",
"    MRI is the modality of choice when a malignant bone tumor is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"     2",
"    </a>",
"    ]. It is the most sensitive modality for evaluation of medullary changes and defining the extent of the lesion and provides the best contrast resolution for demonstrating soft tissue masses and invasion of adjacent structures. Sedation may be required for MRI.",
"   </p>",
"   <p>",
"    Bone scintigraphy may be helpful in evaluating metastatic disease or a multifocal process [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is nonspecific, which limits its use in the initial evaluation of a single bone lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most benign bone tumors are managed with observation (eg, serial examination and radiographs). Symptomatic or aggressive benign tumors (osteoblastoma, periosteal chondroma, chondroblastoma, chondromyxoid fibroma, giant cell tumor, and aneurysmal bone cyst) usually are treated with curettage and bone grafting or excision. The management of specific tumors is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with bone tumors should be referred to and followed by an orthopedic surgeon familiar with these tumors, such as a tumor or pediatric specialist. Small fibromas, fibrous cortical defects, and asymptomatic osteochondromas that are detected incidentally are exceptions and may not require referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone tumors can be classified into several categories according to the matrix, or substance, that they produce:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoid- or bone-forming tumors, including osteoid osteoma and osteoblastoma (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Bone-forming tumors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Cartilage-forming tumors, including osteochondroma (exostosis), chondroma (enchondroma, periosteal chondroma), chondroblastoma, and chondromyxoid fibroma (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Cartilage-forming tumors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Fibrous lesions, including fibrous dysplasia, ossifying fibroma (osteofibrous dysplasia), and nonossifying fibroma (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Fibrous lesions'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Cystic and vascular lesions, including unicameral bone cyst and aneurysmal bone cyst (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Cystic tumors'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BONE-FORMING TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoid osteoma and osteoblastoma are benign bone-forming tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Osteoid osteoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoid osteoma is a benign bone-forming tumor that is characterized by a small radiolucent nidus (usually &lt;1 to 1.5 cm in diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ]. The nidus produces high levels of prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition to prostaglandins, there is some evidence that osteoid osteomas may secrete osteocalcin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Osteoid osteoma typically presents during the second decade [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The lower extremity is most frequently affected; the proximal femur is the most common site. Other common locations are the tibia, the remainder of the femur, and the spine. Boys are affected two to three times as often as girls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with osteoid osteoma typically complain of progressively increasing pain that is worse at night and unrelated to activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ]. The pain is relieved by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    or other nonsteroidal antiinflammatory medications (ie, prostaglandin inhibitors), usually within 20 to 25 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. Lack of relief by nonsteroidal antiinflammatory agents should prompt consideration of other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with lower-extremity lesions may present with limp, swelling, muscular atrophy, leg-length discrepancy, bone deformities, muscle contractures, and local point tenderness at the site of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with spine lesions may present with limp, scoliosis, localized tenderness, restriction of motion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spasm of paravertebral muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/12\">",
"     12",
"    </a>",
"    ]. Children and adolescents with new-onset, painful scoliosis should be evaluated for osteoid osteoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, osteoid osteoma appears as a small, round lucency (nidus) with a sclerotic margin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/16\">",
"     16",
"    </a>",
"    ]. There may be a central ossification (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80598 \" href=\"UTD.htm?7/45/7890\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 25 percent of osteoid osteomas are not obvious on plain radiographs, either because of their location (eg, in the spine) or because cortical thickening obscures the nidus (eg, in the shaft of a long bone such as the tibia or femur), and require computed tomography (CT) or magnetic resonance imaging (MRI) for identification (panel A of radiograph) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70399 \" href=\"UTD.htm?18/40/19072\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of osteoid osteoma includes stress fracture, infection (eg, osteomyelitis, bone abscess), and osteoblastoma. These conditions generally can be distinguished by their characteristic clinical",
"    <span class=\"nowrap\">",
"     and/radiographic",
"    </span>",
"    features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain of stress fractures usually worsens with activity and is relieved with rest; on plain radiographs, stress fractures typically are linear and run perpendicular or at an angle to the cortex, rather than parallel to it [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"       \"Overview of stress fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone infections may have a tract that extends from the lesion toward the nearest growth plate [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pain of osteoblastoma is more generalized and chronic and less responsive to nonsteroidal antiinflammatory medications than that of osteoid osteoma. It typically has a larger nidus, although this may not be visible. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Osteoblastoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of osteoid osteoma depends upon the presence of symptoms. Lesions with symptoms that are tolerable or can be controlled with nonsteroidal antiinflammatory agents may be observed with serial examinations and radiographs every four to six months.",
"   </p>",
"   <p>",
"    Treatment options for symptomatic lesions (eg, intolerable pain, limp, scoliosis) include surgical resection, which may be aided by CT-guided needle localization, or radiofrequency ablation (in certain institutions) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70399 \" href=\"UTD.htm?18/40/19072\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment options may be limited by proximity to vital structures. &nbsp;",
"   </p>",
"   <p>",
"    Prognosis &ndash; Untreated osteoid osteoma spontaneously resolves over the course of several years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/14,22\">",
"     14,22",
"    </a>",
"    ]. Removal of the nidus generally results in resolution of pain. Recurrence is possible if the nidus is not completely removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Osteoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoblastoma is a rare benign bone-forming tumor of unknown etiology.",
"   </p>",
"   <p>",
"    Clinical features &ndash; Osteoblastoma typically presents during the second decade, but may be seen at any age. Boys are affected more often than girls.",
"   </p>",
"   <p>",
"    The most common location of osteoblastoma is the posterior column of the spine (the spinous process, lamina, and pedicles). Other common locations are depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef62766 \" href=\"UTD.htm?23/59/24499\">",
"     figure 2",
"    </a>",
"    ). Tumors in the spine may be difficult to identify on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with osteoblastoma typically complain of chronic pain. The pain is less responsive to nonsteroidal antiinflammatory agents than that of osteoid osteoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. Osteoblastoma uncommonly may cause systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/24\">",
"     24",
"    </a>",
"    ]. Children with spine lesions may present with limp or neurologic symptoms secondary to cord or nerve root compression. Children with lower extremity lesions may present with limp.",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; The radiographic findings of osteoblastoma are variable, and advanced imaging (eg, CT or MRI) often is required for identification. Osteoblastoma may appear similar to osteoid osteoma but is usually larger (&gt;2 cm in diameter); it may appear as an expansive lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78645 \" href=\"UTD.htm?5/49/5906\">",
"     image 3",
"    </a>",
"    ), similar to an aneurysmal bone cyst, or it may have aggressive features, mimicking a malignant neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/15\">",
"     15",
"    </a>",
"    ]. Unlike more aggressive tumors, osteoblastomas rarely extend into the soft tissues.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of osteoblastoma includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"       \"Overview of stress fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infection (eg, osteomyelitis, bone abscess) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteoid osteoma (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Osteoid osteoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Osteosarcoma, a malignant bone tumor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aneurysmal bone cyst (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Aneurysmal bone cyst'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions may require advanced radiographic imaging (eg, CT or MRI) for identification.",
"   </p>",
"   <p>",
"    Treatment &ndash; Treatment for osteoblastoma generally entails curettage and bone grafting. En block excision may be warranted for more aggressive lesions or in regions that permit excision of the bone (eg, fibula). Radiation may be required for spinal lesions when the tumor cannot be completely resected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis &ndash; Untreated osteoblastoma continues to enlarge and may damage the bone and adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/25\">",
"     25",
"    </a>",
"    ]. It may cause progressive neurologic symptoms if it abuts the spinal canal or neural foramina. The prognosis is good if the lesion can be completely removed. The rate of recurrence is up to 20 percent if the lesion has expanded outside the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CARTILAGE-FORMING TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign cartilage-forming tumors of childhood include osteochondroma (exostosis), chondroma (enchondroma, periosteal chondroma), chondroblastoma, and chondromyxoid fibroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Osteochondroma and hereditary multiple osteochondromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An osteochondroma (osteocartilaginous exostosis) is a bony spur arising on the external surface of a bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80362 \" href=\"UTD.htm?43/30/44512\">",
"     image 4",
"    </a>",
"    ). A cartilaginous cap overlies the bony spur and is the source of growth (",
"    <a class=\"graphic graphic_picture graphicRef55666 \" href=\"UTD.htm?40/30/41445\">",
"     picture 2",
"    </a>",
"    ). The cartilage cap is thick in the child, narrows during adolescence, and generally is &lt;1 cm in the adult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hereditary multiple osteochondromas (HMO, also known as hereditary multiple exostoses [HME, MIM #133700, MIM #133701, and MIM #600209]) is characterized by two or more exostoses in the appendicular and axial skeleton (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59501 \" href=\"UTD.htm?12/35/12849\">",
"     image 5",
"    </a>",
"    ). Most cases are caused by autosomal dominant inheritance of a germline mutation in the tumor suppressor genes",
"    <em>",
"     EXT1",
"    </em>",
"    or",
"    <em>",
"     EXT2",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/26\">",
"     26",
"    </a>",
"    ]. However, spontaneous mutations also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of HMO in the general population is approximately 1:50,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Osteochondromas and HMO typically present during the second decade. Males are affected more often than females [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteochondromas usually occur around the knee or the proximal humerus. The distal femur is the most common location.",
"   </p>",
"   <p>",
"    Osteochondromas typically present as a painless mass near a joint or on the axial skeleton, or as a painful mass associated with local trauma. Osteochondromas near the ends of long bones are palpable. Deep osteochondromas (eg, in the axial skeleton) may be an incidental radiographic finding. Osteochondromas can cause pain, functional problems (decreased range of motion), deformity, and pathologic fracture.",
"   </p>",
"   <p>",
"    Osteochondroma can affect nearby growth plates. Patients with HMO may have short stature and angular deformities (ie, varus or valgus deformities) of the upper or lower extremities. The deformities in children with involvement of the wrist and forearm may be severe. Hemiepiphysiodesis can be performed in some cases to allow gradual improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the child with knock-knees\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteochondroma can involve the vertebra and may encroach on the spinal canal. One group recommends screening magnetic resonance of the spine at least once during the growing years for children with HMO [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; Radiographic features include a bony spur (sometimes large) that arises from the surface of the cortex and usually points away from the joint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80362 \" href=\"UTD.htm?43/30/44512\">",
"     image 4",
"    </a>",
"    ). The cortex of the spur is continuous with the cortex of the underlying bone.",
"   </p>",
"   <p>",
"    The cartilage cap is thick in the child (may be &gt;2 cm), narrows during adolescence, and generally is &lt;1 cm in the adult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. If the cartilaginous cap is &gt;1 cm in an adult, malignant transformation to chondrosarcoma is a concern. However, in a review of 67 osteochondromas and 34 secondary chondrosarcomas in adults, no chondrosarcomas had cartilaginous caps &lt;2 cm, and 18 percent of (benign) osteochondromas had a cartilaginous cap &gt;1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/31\">",
"     31",
"    </a>",
"    ]. Biopsy and removal of the entire osteochondroma may be warranted for lesions with a cap &ge;2 cm thick.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of osteochondroma includes parosteal osteosarcoma (a low-grade surface osteosarcoma). Whereas the medullary canal of osteochondromas is always continuous with that of the bone, this is usually not the case with parosteal osteosarcomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H25#H25\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Surface (juxtacortical) osteosarcomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment &ndash; Most osteochondromas can be observed without treatment. Patients should be examined and may have radiographs taken yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for excision may include local irritation or deformity and concern for malignant transformation (cartilage cap &ge;2 cm thick in an adult; increase in size after skeletal maturity; growth disturbance; new onset of symptoms; lesions of the spine, scapula, pelvis, or proximal femur) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,5,32-34\">",
"     3,5,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis &ndash; Osteochondromas grow throughout childhood. They generally stop growing when the physes (growth plates) close and remain static throughout adulthood. There is a moderate risk of recurrence if osteochondromas are incompletely removed before the physes close [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/35\">",
"     35",
"    </a>",
"    ]. Positive prognostic factors (more benign presentation and less functional limitations) include female sex, involvement of &lt;5 sites, and HMO caused by",
"    <em>",
"     EXT2",
"    </em>",
"    mutations. None of these factors was predictive of malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteochondromas may cause local irritation. Lesions of the proximal femur may cause arthritis of the hip joint [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a small lifetime risk of malignant transformation to chondrosarcoma, which occurs during adulthood and most commonly in patients with HMO (in as many as 5 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/26,32,36\">",
"     26,32,36",
"    </a>",
"    ]. Malignant transformation may be heralded by a change in size of an osteochondroma after skeletal maturity or new onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,5,32-34\">",
"     3,5,32-34",
"    </a>",
"    ]. Osteochondromas of the spine, scapula, pelvis, and proximal femur are particularly prone to malignant transformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H5#H5\">",
"     \"Chondrosarcoma\", section on 'Osteochondroma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Enchondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enchondromas are benign cartilage-forming tumors that develop in the medulla (marrow cavity) of long bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82362 \" href=\"UTD.htm?33/9/33951\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Enchondromatosis (Ollier disease, MIM #166000) is defined by multiple enchondromas, often with a unilateral predominance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64618 \" href=\"UTD.htm?2/12/2245\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,6,26\">",
"     3,6,26",
"    </a>",
"    ]. The estimated prevalence is 1 in 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/38\">",
"     38",
"    </a>",
"    ]. Maffucci syndrome is a subtype of enchondromatosis that is characterized by multiple enchondromas and soft tissue hemangiomas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70081 \" href=\"UTD.htm?24/56/25475\">",
"     image 8",
"    </a>",
"    ). Most cases of enchondromatosis and Maffucci syndrome are sporadic and associated with somatic mutations in the isocitrate dehydrogenase-1 and isocitrate dehydrogenase 2 genes (",
"    <em>",
"     IDH1",
"    </em>",
"    and",
"    <em>",
"     IDH2",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Enchondromas typically present during the second decade but can present at any age. Enchondromatosis usually presents in children younger than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enchondromas usually occur in the long bones, particularly the long bones of the hand, followed by the humerus and femur (",
"    <a class=\"graphic graphic_figure graphicRef58774 \" href=\"UTD.htm?24/31/25075\">",
"     figure 3",
"    </a>",
"    ). They generally are central, metaphyseal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. Enchondromas occur with equal frequency in males and females.",
"   </p>",
"   <p>",
"    The signs and symptoms vary depending upon the anatomic site, extent, and distribution of involvement. Most enchondromas are asymptomatic unless a fracture is present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3\">",
"     3",
"    </a>",
"    ]. They often are incidental findings. When symptomatic, clinical manifestations may include widening of the bone, angular deformity, and limb-length discrepancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9\">",
"     9",
"    </a>",
"    ]. In patients with enchondromatosis, enchondromas may arise from the skull base; clinical features include headache and cranial nerve palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; Radiographic features of enchondromas include an oval, well-circumscribed, central lucent lesion, with or without matrix calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82362 \" href=\"UTD.htm?33/9/33951\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/42\">",
"     42",
"    </a>",
"    ]. Matrix calcification usually is not seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. There may be expansion of the surrounding cortex, especially when the lesion is in the hand or foot (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64618 \" href=\"UTD.htm?2/12/2245\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77433 \" href=\"UTD.htm?1/19/1334\">",
"     image 9",
"    </a>",
"    ). Multiple lesions may be present.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of enchondromas includes bony infarcts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63972 \" href=\"UTD.htm?21/27/21937\">",
"     image 10",
"    </a>",
"    ) and low-grade chondrosarcoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55316 \" href=\"UTD.htm?12/51/13107\">",
"     image 11",
"    </a>",
"    ), which must be excluded in patients with enchondroma who have pain without fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H18#H18\">",
"     \"Chondrosarcoma\", section on 'Diagnostic and staging work-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of enchondromas depends upon the presence of symptoms and size. Those that are asymptomatic and small enough not to increase the risk of pathologic fracture may be observed. The risk of fracture is increased when the lesions occur in a weight-bearing bone, are &gt;25 mm in diameter, and involve &gt;50 percent of the diameter of the cortex. The frequency of follow-up depends upon the size, location, and number of lesions.",
"   </p>",
"   <p>",
"    Symptomatic chondromas are treated with curettage and bone grafting; low-grade chondrosarcoma must be excluded in patients with pain in the absence of fracture. Fractures should be permitted to heal before curettage.",
"   </p>",
"   <p>",
"    Prognosis &ndash; Solitary enchondromas usually are self-limited. However, they may continue to grow. Recurrence after curettage and bone graft is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enchondromas, particularly those of the long bones and pelvis, may be complicated by malignant transformation to chondrosarcoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55316 \" href=\"UTD.htm?12/51/13107\">",
"     image 11",
"    </a>",
"    ), which usually occurs after skeletal maturity and may be heralded by the development of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/43\">",
"     43",
"    </a>",
"    ]. Malignant transformation of a solitary enchondroma is extremely rare (&lt;1 percent), but has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/43\">",
"     43",
"    </a>",
"    ]. The risk of malignant transformation is increased (as high as 50 percent) in patients with enchondromatosis (Ollier disease) or Maffucci syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/26,38,44-47\">",
"     26,38,44-47",
"    </a>",
"    ]. Enchondromatosis and Maffucci syndrome also are associated with nonsarcomatous neoplasms, including brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,48,49\">",
"     3,48,49",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Periosteal chondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periosteal chondromas (juxtacortical chondromas) are rare, benign, cartilage-forming tumors that arise from the surface of the cortex, deep in the periosteum, and erode into the cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,6,50\">",
"     3,6,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Periosteal chondroma occurs in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common site is the proximal humerus; the other long bones and small bones of the hands and feet also may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,50\">",
"     3,50",
"    </a>",
"    ]. Clinical features may include pain at the site of the lesion and a palpable nontender hard mass that is fixed to bone.",
"   </p>",
"   <p>",
"    Radiographic features &ndash; On plain radiographs, periosteal chondromas appear as small, scalloped, radiolucent lesions on the outer surface of the cortex in the metaphysis or diaphysis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62037 \" href=\"UTD.htm?24/41/25234\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,6,50-53\">",
"     3,6,50-53",
"    </a>",
"    ]. There is a rim of sclerotic bone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. Calcification is present in approximately one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/51\">",
"     51",
"    </a>",
"    ]. Periosteal reaction is minimal.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of periosteal chondroma includes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonossifying fibroma (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonossifying fibroma'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Soft-tissue tumors, secondarily eroding into the cortical bone",
"     </li>",
"     <li>",
"      Chondrosarcoma, a malignant tumor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteosarcoma, a malignant tumor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; Periosteal chondroma usually is treated with extended curettage or en block excision to minimize the risk of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chondroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondroblastoma is a benign cartilage-forming tumor that usually arises in the epiphyses or apophyses of long bones [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Chondroblastoma typically presents during the teenage years. The most common sites are the epiphysis of the proximal humerus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82162 \" href=\"UTD.htm?35/60/36801\">",
"     image 13",
"    </a>",
"    ), distal femur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57560 \" href=\"UTD.htm?30/45/31442\">",
"     image 14",
"    </a>",
"    ), and proximal tibia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82319 \" href=\"UTD.htm?18/15/18672\">",
"     image 15",
"    </a>",
"    ); 30 percent occur around the knee (",
"    <a class=\"graphic graphic_figure graphicRef69362 \" href=\"UTD.htm?24/28/25027\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/54\">",
"     54",
"    </a>",
"    ]. Chondroblastoma is approximately 1.5 times more common in boys than in girls. Symptoms of chondroblastoma include low-grade joint pain (constant, unrelated to activity) and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9,22\">",
"     9,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, chondroblastomas appear as small, well-defined lesions with a sclerotic border that may cross the physis (growth plate) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66878 \" href=\"UTD.htm?14/0/14336\">",
"     image 16",
"    </a>",
"    ). Matrix calcification may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of chondroblastoma includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant cell tumor, a benign but locally aggressive skeletal tumor that occurs near the growth plate in young adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"       \"Giant cell tumor of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chondromyxoid fibroma. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chondromyxoid fibroma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Avascular necrosis, an abnormality of subchondral bone in which pain is activity related. In contrast, in chondroblastoma, subchondral bone is normal, and pain is constant, unrelated to activity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"       \"Osteonecrosis (avascular necrosis of bone)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aneurysmal bone cyst. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aneurysmal bone cyst'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Osteomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clear cell chondrosarcoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H15#H15\">",
"       \"Chondrosarcoma\", section on 'Clear cell chondrosarcoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; Chondroblastoma is treated with curettage and bone grafting. Reconstruction may be difficult if chondroblastoma involves the articular surface.",
"   </p>",
"   <p>",
"    Prognosis &ndash; The prognosis for patients with chondroblastoma generally is good. Chondroblastoma that involves the articular surface may result in arthritis. Recurrence rates of up to 20 percent are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. In such cases, en bloc resection may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chondromyxoid fibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondromyxoid fibroma is a rare, benign, cartilage-forming tumor of the tubular long bones.",
"   </p>",
"   <p>",
"    Clinical features &ndash; Chondromyxoid fibroma usually presents in the teens or 20s. Approximately one-quarter of cases occur in the proximal tibia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71565 \" href=\"UTD.htm?27/24/28034\">",
"     image 17",
"    </a>",
"    ), with the distal femur and calcaneus being the next most common sites. Males are affected approximately 1.5 times as often as females [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/55\">",
"     55",
"    </a>",
"    ]. Symptoms of chondromyxoid fibroma may include pain and swelling.",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; Chondromyxoid fibroma is an eccentric, intramedullary, lobulated or bubbly lesion in the metaphysis; it has a sclerotic border (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60221 \" href=\"UTD.htm?15/19/15667\">",
"     image 18",
"    </a>",
"    ). It typically is lucent, with a rare chondral matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/22,42\">",
"     22,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of chondromyxoid fibroma includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonossifying fibroma (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonossifying fibroma'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Aneurysmal bone cyst (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Aneurysmal bone cyst'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Chondroblastoma (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Chondroblastoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Osteomyelitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fibrous dysplasia (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Fibrous dysplasia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of chondromyxoid fibroma is curettage and bone grafting.",
"   </p>",
"   <p>",
"    Prognosis &ndash; The prognosis of chondromyxoid fibroma generally is good. There is a 20 percent risk of recurrence, which may require en bloc resection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FIBROUS LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign fibrous lesions of childhood include fibrous dysplasia, osteofibrous dysplasia (ossifying fibroma), and nonossifying fibroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fibrous dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrous dysplasia is a lesion in which portions of the bone are replaced by fibrous connective tissue and poorly formed trabecular bone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. The process originates in the medullary cavity. It is caused by a postzygotic mutation in the guanine nucleotide stimulatory protein (",
"    <em>",
"     GNAS1",
"    </em>",
"    ) gene. It is more of a skeletal dysplasia than a true neoplasm.",
"   </p>",
"   <p>",
"    Fibrous dysplasia may occur in single or multiple bones (monostotic and polyostotic fibrous dysplasia, respectively). The polyostotic form of fibrous dysplasia is known as McCune-Albright syndrome (or Albright syndrome, MIM #174800) and is associated with endocrine abnormalities and caf&eacute;-au-lait spots (",
"    <a class=\"graphic graphic_picture graphicRef80844 \" href=\"UTD.htm?41/51/42815\">",
"     picture 1",
"    </a>",
"    ). Mazabraud syndrome is characterized by fibrous dysplasia and soft tissue myxomas; it overlaps clinically with McCune Albright syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Fibrous dysplasia most commonly presents in the teens or 20s. It may occur in any bone but is most common in the proximal femur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56261 \" href=\"UTD.htm?19/53/20305\">",
"     image 19",
"    </a>",
"    ), tibia, ribs, and skull (",
"    <a class=\"graphic graphic_figure graphicRef69064 \" href=\"UTD.htm?29/2/29731\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. Fibrous dysplasia affects slightly more males than females.",
"   </p>",
"   <p>",
"    Most patients with fibrous dysplasia are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. However, fibrous dysplasia may be painful or cause swelling. It can cause repeated pathologic fractures or severe bone deformity, such as the \"shepherd's crook\" varus deformity of the proximal femur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61700 \" href=\"UTD.htm?6/60/7106\">",
"     image 20",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, fibrous dysplasia appears as a lytic lesion in the metaphysis or diaphysis with a \"ground glass\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62028 \" href=\"UTD.htm?33/35/34353\">",
"     image 21",
"    </a>",
"    ). There is expansion of the bone and possible bowing. The cortical bone is thinned with a scalloped, undulating pattern due to endosteal erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9\">",
"     9",
"    </a>",
"    ]. Periosteal reaction usually is absent unless there is a pathologic fracture.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of fibrous dysplasia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonossifying fibroma (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonossifying fibroma'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Unicameral bone cyst (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Unicameral bone cyst'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Aneurysmal bone cyst (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Aneurysmal bone cyst'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Chondromyxoid fibroma (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Chondromyxoid fibroma'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of fibrous dysplasia depends upon the presence of symptoms. Asymptomatic patients may be observed every six months with serial radiographs. Children with large lesions or lesions in the proximal femur or other weight-bearing bones are observed more frequently.",
"   </p>",
"   <p>",
"    Curettage, bone grafting, and stabilization may be warranted for fibrous dysplasia that is associated with symptoms (pain, deformity) or fracture; however, there is a high rate of recurrence. Autograft should not be used because it will be resorbed. Bisphosphonate therapy is another alternative for symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis &ndash; The deformity of fibrous dysplasia may progress with skeletal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. Fibrous dysplasia usually is static after growth ceases but may be reactivated with pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Fibrous dysplasia often recurs after curettage and bone grafting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ossifying fibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ossifying fibroma (also called osteofibrous dysplasia, intracortical fibrous dysplasia, Jaffe-Campanacci syndrome) is not a tumor, per se, but a deformity-inducing fibro-osseous lesion of the tibia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibula [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The process originates in the cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Ossifying fibroma occurs in children younger than 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It generally affects the tibia and fibula. Clinical features include swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anterolateral bowing of the lower leg. Osteofibrous dysplasia is painful only if it associated with a pathologic fracture.",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; Radiographic features of ossifying fibroma include a lytic thinning of the diaphyseal cortical bone with interspersed sclerosis, causing anterior or anterolateral bowing. There is a sharply circumscribed margin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of ossifying fibroma includes monostotic fibrous dysplasia (which originates in the medulla rather than the cortex), adamantinoma (a low-grade malignant bone tumor), and nonossifying fibroma. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Fibrous dysplasia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Nonossifying fibroma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of ossifying fibroma is usually observation. Asymptomatic patients may be observed every six months with serial radiographs. Children with large lesions or lesions in the proximal femur or other weight-bearing bones are seen more frequently (eg, every three to four months). Excision, bone graft, and correction of bony deformity may be warranted for lesions that are symptomatic (ie, with pain or deformity) after skeletal maturity.",
"   </p>",
"   <p>",
"    Prognosis &ndash; Ossifying fibroma is noninvasive. However, it will recur if it is excised before skeletal maturity. Excision after skeletal maturity is usually successful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nonossifying fibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonossifying fibroma is a benign fibrous lesion that is also known as metaphyseal cortical defect, fibrous cortical defect, and benign metaphyseal bone scar. It is a developmental defect in which areas that normally ossify are filled with fibrous connective tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Nonossifying fibroma usually is an incidental radiographic finding in teenagers. It occurs most commonly in the distal femur, followed by the distal tibia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68410 \" href=\"UTD.htm?41/19/42291\">",
"     image 22",
"    </a>",
"    ), and the proximal tibia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79406 \" href=\"UTD.htm?17/37/18001\">",
"     image 23",
"    </a>",
"    ). Girls are affected as often as boys [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonossifying fibroma usually is asymptomatic and discovered incidental to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. Large lesions may be associated with pathologic fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, nonossifying fibromas appear as small, well-defined, eccentric, expansile, lytic lesions located in the metaphysis with scalloped sclerotic borders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Multiple lesions may be present.",
"   </p>",
"   <p>",
"    Nonossifying fibromas may have an atypical appearance as they fill with normal bone before they disappear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. When there is a concomitant pathologic fracture, nonossifying fibroma may have a more aggressive radiographic appearance, but it should not be mistaken for malignant tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of nonossifying fibroma includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chondromyxoid fibroma (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Chondromyxoid fibroma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fibrous dysplasia (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Fibrous dysplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Langerhans cell histiocytosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"       \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; Small, asymptomatic nonossifying fibromas that are discovered incidentally do not require any further follow-up. Parents are simply counseled to bring their child in if the area becomes painful. In younger children, the lesions may grow relative to adjacent bone, increasing the risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Curettage and bone grafting may be warranted for lesions causing pain or to prevent pathologic fracture if the lesion is greater than 50 percent of the diameter of the bone or is in a high-stress area (eg, distal femoral metaphysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis &ndash; The prognosis for nonossifying fibroma generally is excellent. They usually fill in during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk of recurrence is lower than for other benign tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CYSTIC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign cystic tumors include unicameral bone cysts and aneurysmal bone cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Unicameral bone cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unicameral bone cysts (simple bone cysts, solitary bone cysts) are fluid-filled lesions with a fibrous lining [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Unicameral bone cysts generally occur in the first 20 years of life. The proximal humerus and femur are the most common locations. Unicameral bone cysts occur with equal frequency in boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unicameral bone cysts commonly present with a pathologic fracture. However, they may be an incidental radiographic finding. Symptoms may include localized pain, limp, or failure to use the extremity normally [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, unicameral bone cysts (UBCs) appear as well-marginated cystic lesions of the metaphysis or metadiaphysis without reactive sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,5\">",
"     1,5",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50405 \" href=\"UTD.htm?38/41/39569\">",
"     image 24",
"    </a>",
"    ). The lesion usually involves the full diameter of bone, with expansion of the cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UBCs with pathologic fractures may be indicated by the \"fallen fragment\" or \"fallen leaf\" sign, in which a fragment of bone falls to the bottom of the cyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65224 \" href=\"UTD.htm?4/34/4642\">",
"     image 25",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9,65\">",
"     9,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of UBC includes aneurysmal bone cyst and fibrous dysplasia. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Aneurysmal bone cyst'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Fibrous dysplasia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment &ndash; The treatment of UBCs is observation with serial radiographs every four to six months. Activity restrictions are often necessary to avoid pathologic fracture. Alternatively, UBCs may be aspirated and injected with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Although it has never been conclusively proven, some authors believe that glucocorticoid injection may hasten the resolution of the cyst and thus allow patients to return to normal activities. Numerous substances have been injected into UBCs, including bone marrow, growth factors, and demineralized bone graft. None have been proven to be as effective as or more effective than steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Curettage and bone grafting rarely are required for large lesions that compromise the structural integrity of the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis &ndash; UBCs spontaneously resolve in all patients. However, resolution may not occur until after skeletal maturity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Aneurysmal bone cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal bone cysts are benign expansile vascular lesions that consist of blood-filled channels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. They may grow rapidly and destroy bone. Aneurysmal bone cysts generally are solitary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"     1",
"    </a>",
"    ]. They may be primary or related to other benign bone lesions (eg, giant cell tumor, osteoblastoma, chondroblastoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features &ndash; Aneurysmal bone cysts generally occur in adolescents. They may be found in any bone but are most common in the posterior spinal elements, femur, and tibia (",
"    <a class=\"graphic graphic_figure graphicRef56710 \" href=\"UTD.htm?26/11/26803\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/71\">",
"     71",
"    </a>",
"    ]. Aneurysmal bone cysts are slightly more common in girls than in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysmal bone cysts typically cause localized pain. They may present with pathologic fracture, limp, or swelling as the lesion increases in size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Lesions in the spine may be associated with neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/72\">",
"     72",
"    </a>",
"    ]. Lesions that cross the growth plate may cause growth arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings &ndash; On plain radiographs, aneurysmal bone cysts appear as aggressive, expansile, lytic metaphyseal lesions with an \"eggshell\" sclerotic rim (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80871 \" href=\"UTD.htm?19/19/19760\">",
"     image 26",
"    </a>",
"    ). Pathologic fracture or periosteal reaction may be present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68448 \" href=\"UTD.htm?22/59/23487\">",
"     image 27",
"    </a>",
"    ). The lesions are sharply circumscribed. They may have a \"soap bubble\" appearance secondary to the reinforcement of the remaining trabeculae that support the bone structure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. The cortex is usually intact, although it may be thin.",
"   </p>",
"   <p>",
"    Differential diagnosis &ndash; The differential diagnosis of aneurysmal bone cyst includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unicameral bone cyst (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Unicameral bone cyst'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Giant cell tumor, a benign but locally aggressive skeletal tumor that occurs in young adults (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"       \"Giant cell tumor of bone\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteosarcoma, a malignant bone tumor (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteoblastoma (in the spine) (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Osteoblastoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chondroblastoma (if they cross the growth plate) (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Chondroblastoma'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment &ndash; Aneurysmal bone cysts are treated with excision, curettage, and bone grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/70,73\">",
"     70,73",
"    </a>",
"    ]. Chemical cauterization or cryotherapy may be required.",
"   </p>",
"   <p>",
"    Prognosis &ndash; Aneurysmal bone cysts are locally aggressive and destructive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"     6",
"    </a>",
"    ]. They continue to expand until treated and may recur after excision (in 10 to 50 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/60/24522/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER BONE TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Langerhans cell histiocytosis of bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis (LCH) of bone is a benign form of LCH that is localized to bone. Patients may present with a solitary lesion (monostotic) or multiple sites of involvement (polyostotic). LCH of bone is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Giant cell tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell tumor of bone is a relatively rare, benign, but locally aggressive osteolytic skeletal neoplasm of young adults. It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"     \"Giant cell tumor of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign bone tumors often are discovered incidentally during evaluation of trauma or another condition. Symptoms of benign bone tumors, when they occur, may include localized pain, swelling, deformity, or pathologic fracture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most benign bone tumors can be diagnosed with plain radiographs. Characteristic clinical and radiographic features are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef69193 \" href=\"UTD.htm?23/34/24110\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most benign bone tumors are managed with serial examinations and radiographs. Symptomatic or aggressive benign tumors may be treated with curettage and bone grafting or excision. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign bone tumors of childhood can be classified according to the matrix, or substance, that they produce: osteoid- or bone-forming tumors, cartilage-forming tumors, fibrous lesions, and cystic tumors. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoid- or bone-forming tumors include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Osteoid osteoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80598 \" href=\"UTD.htm?7/45/7890\">",
"       image 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Osteoid osteoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Osteoblastoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78645 \" href=\"UTD.htm?5/49/5906\">",
"       image 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Osteoblastoma'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cartilage-forming tumors include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Osteochondroma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80362 \" href=\"UTD.htm?43/30/44512\">",
"       image 4",
"      </a>",
"      ) and hereditary multiple osteochondromas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59501 \" href=\"UTD.htm?12/35/12849\">",
"       image 5",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Osteochondroma and hereditary multiple osteochondromas'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Solitary enchondroma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82362 \" href=\"UTD.htm?33/9/33951\">",
"       image 6",
"      </a>",
"      ), enchondromatosis (Ollier syndrome) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64618 \" href=\"UTD.htm?2/12/2245\">",
"       image 7",
"      </a>",
"      ), and Maffucci syndrome (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70081 \" href=\"UTD.htm?24/56/25475\">",
"       image 8",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Enchondroma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Periosteal chondroma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62037 \" href=\"UTD.htm?24/41/25234\">",
"       image 12",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Periosteal chondroma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chondroblastoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66878 \" href=\"UTD.htm?14/0/14336\">",
"       image 16",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Chondroblastoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chondromyxoid fibroma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71565 \" href=\"UTD.htm?27/24/28034\">",
"       image 17",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Chondromyxoid fibroma'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrous lesions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fibrous dysplasia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56261 \" href=\"UTD.htm?19/53/20305\">",
"       image 19",
"      </a>",
"      ) and polyostotic fibrous dysplasia (McCune-Albright syndrome) (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Fibrous dysplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ossifying fibroma (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Ossifying fibroma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Nonossifying fibroma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68410 \" href=\"UTD.htm?41/19/42291\">",
"       image 22",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonossifying fibroma'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic and vascular lesions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unicameral bone cyst (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65224 \" href=\"UTD.htm?4/34/4642\">",
"       image 25",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Unicameral bone cyst'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Aneurysmal bone cyst (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80871 \" href=\"UTD.htm?19/19/19760\">",
"       image 26",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Aneurysmal bone cyst'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/1\">",
"      Yildiz C, Erler K, Atesalp AS, Basbozkurt M. Benign bone tumors in children. Curr Opin Pediatr 2003; 15:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/2\">",
"      Wyers MR. Evaluation of pediatric bone lesions. Pediatr Radiol 2010; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     Springfield DS, Gebhardt MC. Bone and soft tissue tumors. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.493.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/4\">",
"      Faivre L, Nivelon-Chevallier A, Kottler ML, et al. Mazabraud syndrome in two patients: clinical overlap with McCune-Albright syndrome. Am J Med Genet 2001; 99:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/5\">",
"      Biermann JS. Common benign lesions of bone in children and adolescents. J Pediatr Orthop 2002; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/6\">",
"      Copley L, Dormans JP. Benign pediatric bone tumors. Evaluation and treatment. Pediatr Clin North Am 1996; 43:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/7\">",
"      Kim S, Lee S, Arsenault DA, et al. Pediatric rib lesions: a 13-year experience. J Pediatr Surg 2008; 43:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/8\">",
"      Wenaden AE, Szyszko TA, Saifuddin A. Imaging of periosteal reactions associated with focal lesions of bone. Clin Radiol 2005; 60:439.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdjian MO. Generalized affectations of the muscular skeletal system. In: Clinical Pediatric Orthopedics The Art of Diagnosis and Principles of Management, Appleton &amp; Lange, Stamford, CT 1997. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/10\">",
"      Confavreux CB, Borel O, Lee F, et al. Osteoid osteoma is an osteocalcinoma affecting glucose metabolism. Osteoporos Int 2012; 23:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/11\">",
"      Kaweblum M, Lehman WB, Bash J, et al. Diagnosis of osteoid osteoma in the child. Orthop Rev 1993; 22:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/12\">",
"      Orlowski JP, Mercer RD. Osteoid osteoma in children and young adults. Pediatrics 1977; 59:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/13\">",
"      Cohen MD, Harrington TM, Ginsburg WW. Osteoid osteoma: 95 cases and a review of the literature. Semin Arthritis Rheum 1983; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/14\">",
"      Kneisl JS, Simon MA. Medical management compared with operative treatment for osteoid-osteoma. J Bone Joint Surg Am 1992; 74:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/15\">",
"      Greenspan A. Benign bone-forming lesions: osteoma, osteoid osteoma, and osteoblastoma. Clinical, imaging, pathologic, and differential considerations. Skeletal Radiol 1993; 22:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/16\">",
"      Iyer RS, Chapman T, Chew FS. Pediatric bone imaging: diagnostic imaging of osteoid osteoma. AJR Am J Roentgenol 2012; 198:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/17\">",
"      Spouge AR, Thain LM. Osteoid osteoma: MR imaging revisited. Clin Imaging 2000; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/18\">",
"      Assoun J, Richardi G, Railhac JJ, et al. Osteoid osteoma: MR imaging versus CT. Radiology 1994; 191:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/19\">",
"      Vigorita VJ, Ghelman B. Localization of osteoid osteomas--use of radionuclide scanning and autoimaging in identifying the nidus. Am J Clin Pathol 1983; 79:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/20\">",
"      Papathanassiou ZG, Megas P, Petsas T, et al. Osteoid osteoma: diagnosis and treatment. Orthopedics 2008; 31:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/21\">",
"      Gasbarrini A, Cappuccio M, Bandiera S, et al. Osteoid osteoma of the mobile spine: surgical outcomes in 81 patients. Spine (Phila Pa 1976) 2011; 36:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/22\">",
"      Aboulafia AJ, Kennon RE, Jelinek JS. Begnign bone tumors of childhood. J Am Acad Orthop Surg 1999; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/23\">",
"      McLeod RA, Dahlin DC, Beabout JW. The spectrum of osteoblastoma. AJR Am J Roentgenol 1976; 126:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/24\">",
"      Mirra JM, Cove K, Theros E, et al. A case of osteoblastoma associated with severe systemic toxicity. Am J Surg Pathol 1979; 3:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/25\">",
"      Boriani S, Capanna R, Donati D, et al. Osteoblastoma of the spine. Clin Orthop Relat Res 1992; :37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/26\">",
"      Pannier S, Legeai-Mallet L. Hereditary multiple exostoses and enchondromatosis. Best Pract Res Clin Rheumatol 2008; 22:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/27\">",
"      Bov&eacute;e JV. Multiple osteochondromas. Orphanet J Rare Dis 2008; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/28\">",
"      Schmale GA, Conrad EU 3rd, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 1994; 76:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/29\">",
"      Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet 1995; 55:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/30\">",
"      Roach JW, Klatt JW, Faulkner ND. Involvement of the spine in patients with multiple hereditary exostoses. J Bone Joint Surg Am 2009; 91:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/31\">",
"      Bernard SA, Murphey MD, Flemming DJ, Kransdorf MJ. Improved differentiation of benign osteochondromas from secondary chondrosarcomas with standardized measurement of cartilage cap at CT and MR imaging. Radiology 2010; 255:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/32\">",
"      Garrison RC, Unni KK, McLeod RA, et al. Chondrosarcoma arising in osteochondroma. Cancer 1982; 49:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/33\">",
"      Ahmed AR, Tan TS, Unni KK, et al. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 2003; :193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/34\">",
"      Pierz KA, Womer RB, Dormans JP. Pediatric bone tumors: osteosarcoma ewing's sarcoma, and chondrosarcoma associated with multiple hereditary osteochondromatosis. J Pediatr Orthop 2001; 21:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/35\">",
"      Chin KR, Kharrazi FD, Miller BS, et al. Osteochondromas of the distal aspect of the tibia or fibula. Natural history and treatment. J Bone Joint Surg Am 2000; 82:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/36\">",
"      Pedrini E, Jennes I, Tremosini M, et al. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of \"protective\" and \"risk\" factors. J Bone Joint Surg Am 2011; 93:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/37\">",
"      Malag&oacute;n V. Development of hip dysplasia in hereditary multiple exostosis. J Pediatr Orthop 2001; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/38\">",
"      Silve C, J&uuml;ppner H. Ollier disease. Orphanet J Rare Dis 2006; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/39\">",
"      Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/40\">",
"      Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/41\">",
"      D'Angelo L, Massimi L, Narducci A, Di Rocco C. Ollier disease. Childs Nerv Syst 2009; 25:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/42\">",
"      Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skeletal Radiol 1997; 26:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/43\">",
"      Altay M, Bayrakci K, Yildiz Y, et al. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci 2007; 12:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/44\">",
"      Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas associated with Ollier's disease. Cancer 1987; 59:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/45\">",
"      Schwartz HS, Zimmerman NB, Simon MA, et al. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987; 69:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/46\">",
"      Albregts AE, Rapini RP. Malignancy in Maffucci's syndrome. Dermatol Clin 1995; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/47\">",
"      Verdegaal SH, Bov&eacute;e JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011; 16:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/48\">",
"      Lewis RJ, Ketcham AS. Maffucci's syndrome: functional and neoplastic significance. Case report and review of the literature. J Bone Joint Surg Am 1973; 55:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/49\">",
"      Ranger A, Szymczak A. Do intracranial neoplasms differ in Ollier disease and maffucci syndrome? An in-depth analysis of the literature. Neurosurgery 2009; 65:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/50\">",
"      Brien EW, Mirra JM, Luck JV Jr. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors. Skeletal Radiol 1999; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/51\">",
"      deSantos LA, Spjut HJ. Periosteal chondroma: a radiographic spectrum. Skeletal Radiol 1981; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/52\">",
"      Bauer TW, Dorfman HD, Latham JT Jr. Periosteal chondroma. A clinicopathologic study of 23 cases. Am J Surg Pathol 1982; 6:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/53\">",
"      Boriani S, Bacchini P, Bertoni F, Campanacci M. Periosteal chondroma. A review of twenty cases. J Bone Joint Surg Am 1983; 65:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/54\">",
"      Dahlin DC, Ivins JC. Benign chondroblastoma. A study of 125 cases. Cancer 1972; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/55\">",
"      Gherlinzoni F, Rock M, Picci P. Chondromyxoid fibroma. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am 1983; 65:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/56\">",
"      Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 2001; :6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/57\">",
"      Mansoori LS, Catel CP, Rothman MS. Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review. Endocr Pract 2010; 16:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/58\">",
"      Stevens-Simon C, Stewart J, Nakashima II, White M. Exacerbation of fibrous dysplasia associated with an adolescent pregnancy. J Adolesc Health 1991; 12:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/59\">",
"      Mintz MC, Dalinka MK, Schmidt R. Aneurysmal bone cyst arising in fibrous dysplasia during pregnancy. Radiology 1987; 165:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/60\">",
"      Campanacci M, Laus M. Osteofibrous dysplasia of the tibia and fibula. J Bone Joint Surg Am 1981; 63:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/61\">",
"      Kahn LB. Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. Skeletal Radiol 2003; 32:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/62\">",
"      McCaffrey M, Letts M, Carpenter B, et al. Osteofibrous dysplasia: a review of the literature and presentation of an additional 3 cases. Am J Orthop (Belle Mead NJ) 2003; 32:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/63\">",
"      Wang JW, Shih CH, Chen WJ. Osteofibrous dysplasia (ossifying fibroma of long bones). A report of four cases and review of the literature. Clin Orthop Relat Res 1992; :235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/64\">",
"      Steiner GC. Fibrous cortical defect and nonossifying fibroma of bone. A study of the ultrastructure. Arch Pathol 1974; 97:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/65\">",
"      Reynolds J. The \"fallen fragment sign\" in the diagnosis of unicameral bone cysts. Radiology 1969; 92:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/66\">",
"      Cho HS, Oh JH, Kim HS, et al. Unicameral bone cysts: a comparison of injection of steroid and grafting with autologous bone marrow. J Bone Joint Surg Br 2007; 89:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/67\">",
"      Chang CH, Stanton RP, Glutting J. Unicameral bone cysts treated by injection of bone marrow or methylprednisolone. J Bone Joint Surg Br 2002; 84:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/68\">",
"      Wright JG, Yandow S, Donaldson S, et al. A randomized clinical trial comparing intralesional bone marrow and steroid injections for simple bone cysts. J Bone Joint Surg Am 2008; 90:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/69\">",
"      Singh S, Dhammi IK, Arora A, Kumar S. Unusually large solitary unicameral bone cyst: case report. J Orthop Sci 2003; 8:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/70\">",
"      Shih HN, Chen YJ, Huang TJ, et al. Semistructural allografting in bone defects after curettage. J Surg Oncol 1998; 68:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/71\">",
"      Dahlin DC, McLeod RA. Aneurysmal bone cyst and other nonneoplastic conditions. Skeletal Radiol 1982; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/72\">",
"      Novais EN, Rose PS, Yaszemski MJ, Sim FH. Aneurysmal bone cyst of the cervical spine in children. J Bone Joint Surg Am 2011; 93:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/60/24522/abstract/73\">",
"      Ibrahim T, Howard AW, Murnaghan ML, Hopyan S. Percutaneous curettage and suction for pediatric extremity aneurysmal bone cysts: is it adequate? J Pediatr Orthop 2012; 32:842.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6294 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24522=[""].join("\n");
var outline_f23_60_24522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Advanced imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Referral indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BONE-FORMING TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Osteoid osteoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Osteoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CARTILAGE-FORMING TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Osteochondroma and hereditary multiple osteochondromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Enchondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Periosteal chondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chondroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chondromyxoid fibroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FIBROUS LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fibrous dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ossifying fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nonossifying fibroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CYSTIC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Unicameral bone cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Aneurysmal bone cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER BONE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Langerhans cell histiocytosis of bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Giant cell tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6294|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/45/7890\" title=\"diagnostic image 1\">",
"      Osteoid osteoma xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/40/19072\" title=\"diagnostic image 2\">",
"      Osteoid osteoma RF ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/49/5906\" title=\"diagnostic image 3\">",
"      Osteoblastoma xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/30/44512\" title=\"diagnostic image 4\">",
"      Osteochondroma proximal femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/35/12849\" title=\"diagnostic image 5\">",
"      Multiple exostoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/9/33951\" title=\"diagnostic image 6\">",
"      Solitary enchondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/12/2245\" title=\"diagnostic image 7\">",
"      Enchondromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/56/25475\" title=\"diagnostic image 8\">",
"      Maffucci syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/19/1334\" title=\"diagnostic image 9\">",
"      Enchondroma hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/27/21937\" title=\"diagnostic image 10\">",
"      Enchondroma vs infarct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/51/13107\" title=\"diagnostic image 11\">",
"      Enchondroma malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/41/25234\" title=\"diagnostic image 12\">",
"      Periosteal chondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/60/36801\" title=\"diagnostic image 13\">",
"      Chondroblastoma humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/45/31442\" title=\"diagnostic image 14\">",
"      Chondroblastoma knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/15/18672\" title=\"diagnostic image 15\">",
"      Chondroblastoma tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/0/14336\" title=\"diagnostic image 16\">",
"      Chondroblastoma extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/24/28034\" title=\"diagnostic image 17\">",
"      Chondromyxoid fibroma tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/19/15667\" title=\"diagnostic image 18\">",
"      Chondromyxoid fibroma femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/53/20305\" title=\"diagnostic image 19\">",
"      Fibrous dysplasia femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/60/7106\" title=\"diagnostic image 20\">",
"      Shepherds crook deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/35/34353\" title=\"diagnostic image 21\">",
"      Polyostotic fibrous dysplas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/19/42291\" title=\"diagnostic image 22\">",
"      Nonossifying fibroma distal tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/37/18001\" title=\"diagnostic image 23\">",
"      Nonossifying fibroma prox tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/41/39569\" title=\"diagnostic image 24\">",
"      Unicameral bone cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/34/4642\" title=\"diagnostic image 25\">",
"      Fallen fragment sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/19/19760\" title=\"diagnostic image 26\">",
"      Aneurysmal bone cyst fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/59/23487\" title=\"diagnostic image 27\">",
"      Aneurysmal bone cyst ulna",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6294|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13864\" title=\"figure 1\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/59/24499\" title=\"figure 2\">",
"      Osteoblastoma sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25075\" title=\"figure 3\">",
"      Solitary enchondroma sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/28/25027\" title=\"figure 4\">",
"      Chondroblastoma sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/2/29731\" title=\"figure 5\">",
"      Fibrous dysplasia sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/11/26803\" title=\"figure 6\">",
"      Aneurysmal bone cyst sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6294|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/51/42815\" title=\"picture 1\">",
"      Cafe au lait spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/30/41445\" title=\"picture 2\">",
"      Osteochondroma cross-section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6294|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24110\" title=\"table 1\">",
"      Overview benign bone tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_60_24523="PPSV23 schedule for high-risk children older than two years";
var content_f23_60_24523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged &ge;2 years with underlying medical conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule for PPSV23",
"       </td>",
"       <td class=\"subtitle1\">",
"        Revaccination with PPSV23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia",
"       </td>",
"       <td>",
"        1 dose of PPSV23 administered at age &ge;2 years and &ge;8 weeks after last indicated dose of PCV13",
"       </td>",
"       <td>",
"        1 dose 5 years after the first dose of PPSV23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunocompetent children with chronic illness*",
"       </td>",
"       <td>",
"        1 dose of PPSV23 administered at age &ge;2 years and &ge;8 weeks after last indicated dose of PCV13",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Chronic heart disease, chronic lung disease, diabetes mellitus, cerebrospinal fluid leaks, or cochlear implant.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24523=[""].join("\n");
var outline_f23_60_24523=null;
var title_f23_60_24524="Hepatic resection for metastatic colorectal cancer";
var content_f23_60_24524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of hepatic resection for metastatic colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author and year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five year OS, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival, months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hughes KS; 1986",
"       </td>",
"       <td>",
"        607",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scheele J; 1995",
"       </td>",
"       <td>",
"        434",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nordlinger B; 1996",
"       </td>",
"       <td>",
"        1568",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jamison RL; 1997",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fong Y; 1999",
"       </td>",
"       <td>",
"        1001",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iwatsuki S; 1999",
"       </td>",
"       <td>",
"        305",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choti M; 2002",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdalla E; 2004",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fernandez FG; 2004",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wei AC; 2006",
"       </td>",
"       <td>",
"        423",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rees M; 2008",
"       </td>",
"       <td>",
"        929",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        de Jong M; 2009",
"       </td>",
"       <td>",
"        1669",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morris EJ; 2010",
"       </td>",
"       <td>",
"        3116",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; OS: overall survival.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24524=[""].join("\n");
var outline_f23_60_24524=null;
var title_f23_60_24525="Pegintron Rebetol dose mod";
var content_f23_60_24525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53213%7EGAST%2F75290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53213%7EGAST%2F75290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for dose modification and discontinuation of PegIntron (peginterferon) or PegIntron/REBETOL (ribavirin) for hematologic toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory values",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peginterferon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ribavirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Hemoglobin",
"       </td>",
"       <td>",
"        &lt;10 g/dL*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Decrease by 200 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;8.5 g/dL",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        White blood cell count",
"       </td>",
"       <td>",
"        &lt;1.5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Neutrophil count",
"       </td>",
"       <td>",
"        &lt;0.75 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;0.5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Platelet count",
"       </td>",
"       <td>",
"        &lt;50 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Reduce dose by 50 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;25 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /L",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"       <td>",
"        Permanently discontinue",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients with a history of stable cardiac disease receiving PegIntron in combination with ribavirin, the PegIntron dose should be reduced by half and the ribavirin dose by 200 mg/day if a &gt;2 g/dL decrease in hemoglobin is observed during any 4-week period. Both PegIntron and ribavirin should be permanently discontinued if patients have hemoglobin levels &lt;12 g/dL after this ribavirin dose reduction.",
"    </div>",
"    <div class=\"reference\">",
"     Table adapted from: Product information: Peg Intron&reg; (peginterferon alfa-2b). Schering Corporation, Kenilworth, NJ. Available online at: file://www.spfiles.com/pipeg-intron.pdf (Accessed on September 13, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PEGASYS (peginterferon)/COPEGUS (ribavirin) dosage modification guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory values",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Discontinue if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PEGASYS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANC &ge;750/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Maintain 180 mcg",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         ANC &lt;500/mm",
"         <sup>",
"          3",
"         </sup>",
"         , treatment should be suspended until ANC values return to more than 1000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"        <p>",
"         Reinstitute at 90&nbsp;mcg and monitor ANC",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANC &lt;750/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Reduce to 135 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet &ge;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Maintain 180 mcg",
"       </td>",
"       <td rowspan=\"2\">",
"        Platelet count &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Reduce to 90 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        COPEGUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin in patients with no cardiac disease",
"       </td>",
"       <td>",
"        Reduce to 600 mg/day* if &lt;10 g/dL",
"       </td>",
"       <td>",
"        &lt;8.5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin in patients with history of stable cardiac disease",
"       </td>",
"       <td>",
"        Reduce to 600 mg/day* if &ge;2 g/dL decrease in hemoglobin during any 4-week period treatment",
"       </td>",
"       <td>",
"        &lt;12 g/dL despite 4 weeks at reduced dose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One 200 mg tablet in the morning and two 200 mg tablets in the evening.",
"    </div>",
"    <div class=\"reference\">",
"     Table from: Pegasys (peginterferon alfa-2a) Prescribing Information and Medication Guide. Roche Pharmaceuticals, Nutley, NJ. Available online at: file://www.rocheusa.com/products/pegasys/pi.pdf (Accessed on September 4, 2007).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24525=[""].join("\n");
var outline_f23_60_24525=null;
var title_f23_60_24526="Positve predictive of value stress test results";
var content_f23_60_24526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Positive predictive value of findings from stress testing after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis of studies reporting risk stratification after a myocardial infarction (MI). The positive predictive value (PPV) of different types of stress tests (ECG, myocardial perfusion imaging, echocardiography) for cardiac death rate or the combined end point of cardiac death or MI was lower in patients treated with a thrombolytic agent. Markers of left ventricular function (eg, peak left ventricular ejection fraction) were better predictors of outcome than markers of ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Shaw LJ, Peterson ED, Kesler K, et al. Am J Cardiol 1996; 78:1327.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24526=[""].join("\n");
var outline_f23_60_24526=null;
var title_f23_60_24527="Vertebral artery flow in subclavian steal syndrome";
var content_f23_60_24527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vertebral artery flow in subclavian steal syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulse-waved Doppler spectral display shows retrograde flow in the left vertebral artery in a patient with a hemodynamically significant left subclavian artery stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Spittell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_60_24527=[""].join("\n");
var outline_f23_60_24527=null;
